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The aim of this project was to develop bioprinted 3D full-thickness human skin 
equivalents (HSEs) which could be exploited for safety testing of biologics in-vitro. In 
this study, handmade 3D HSEs in a 24-well format were first optimised, and the 
structure of the 24-well HSEs were shown to be comparable to physiological healthy 
human skin. To improve the feasibility of bioprinting 3D HSEs the overall size of the 
equivalents was reduced by scaling the HSEs to a 96-well plate format using prototype 
96-well Alvetex® inserts. Histological analysis of the optimised 96-well skin equivalents 
showed these to be similar to both the 24-well HSEs and physiological human skin.  
To demonstrate that skin cells could be bioprinted in the high densities required to 
create 3D HSEs, cells were printed using a Jetlab 4 Tabletop printer and solenoid 
microvalves. Fibroblasts were printed at concentrations of 1x106 cells/mL, 10x106 
cells/mL, 20x106 cells/mL and 40x106 cells/mL. Cell count and viability immediately 
post printing demonstrated that microvalves could be used to reliably dispense a high 
density of cells over 1 hour with minimal cell death. 96-well HSEs were then bioprinted 
and compared to handmade 24-well and 96-well HSEs in addition to human skin using 
histological techniques. Fully autologous 96-well HSEs were then bioprinted and co-
cultured in-vitro with autologous peripheral blood mononuclear cells (PBMCs) in the 
presence and absence of biologics known to cause (OKT3) or not to cause 
(Natalizumab) immunotoxicity. Investigation of supernatants revealed significant 
proinflammatory cytokine responses (interferon gamma (IFN-γ)) in co-cultures treated 
with OKT3 when compared to negative controls.  
This research developed a 96-well format bioprinted HSE and demonstrated the 
feasibility of using bioprinted 3D tissue equivalents for in-vitro immunotoxicity testing 
of biologics. In conclusion, microvalve based bioprinting technology can be used to 
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Chapter 1 Project Aims and Literature Review 
1.1 Introduction 
As human tissue is not easily obtainable and in limited supply for preclinical human in-
vitro testing, preclinical animal testing is commonly used during the drug development 
process. However animal models not only raise ethical concerns but the results may 
not be a true indication of the drugs effect on humans in clinic (Stebbings et al. 2007). 
Mostly drugs can fail when first tested in humans, even after successfully passing 
preclinical animal testing. This can be because the human specific immunogenic 
properties of the drug are not detected during animal testing and only first become 
apparent during clinical trials. This contributes to the high failure rate that the 
pharmaceutical industry experiences when taking drugs to human clinical trials (Hay 
et al. 2014). Such failures can have disastrous consequences such as the 2006 
Northwick Park drug trial, which later came to be more commonly known as the 
“Elephant man trial”. As reported by Stebbings et al, the CD28-specific monoclonal 
antibody (mAb) TGN1412 was used in the Northwick Park drug trial. Preclinical tests 
of TGN1412 in Cynomolgus macaques showed little lymphocyte activation in response 
to TGN1412 (Stebbings et al. 2007). The trial resulted in six of the eight healthy 
volunteers in clinic suffering multiple organ failure (Attarwala 2010). The remaining two 
volunteers had received a placebo and suffered no adverse effects. Post-trial 
investigations of TGN1412 demonstrated that exposure of human peripheral blood 
monocytes (PBMCs) to TGN1412 triggered a strong systematic immune response 
(Stebbings et al. 2007). In clinical terms this immune response is referred to as a 
‘cytokine storm’ (Stebbings et al. 2007). Such adverse events highlight the need for 
commercially available preclinical testing of drug candidates in fully autologous human 
systems. 
The drug development process is a lengthy and costly venture and so the general aim 
of early testing of biologics tends to be “fail early, fail cheap”. This refers to the timely 
identification of inappropriate drugs that are in the early stages of the development 
process with an aim to minimise the loss of significant time and financial investment 
into a product that will likely raise safety issues during clinical trials. The use of human 
in-vitro assays which could predict human adverse events in-vivo would allow more 
accurate earlier detection of immunotoxicity in the early stages of drug development   
and at the pre-clinical stage before costly clinical trials (Visk 2015).  
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One such example of a preclinical human in-vitro assay is the Skimune® assay 
developed by Alcyomics Ltd to determine adverse responses to systemic therapies 
(Ahmed et al. 2016). As a preclinical assay that utilises immune cells combined with 
human tissue, Skimune® provides the pharmaceutical industry with a possible 
alternative to animal models, which may bridge the gap between preclinical animal 
studies and human clinical trials. Skimune® uses human skin biopsies for in-vitro 
explant tests along with autologous peripheral blood monocytes (PBMCs) to predict 
adverse events of drugs and sensitization to chemicals. Current assays are mostly 
single cell based, or tissue based (Stebbings et al. 2007), therefore the combination of 
using immune cells and tissue from the same donor offers an attractive proposition. 
The use of  human immune cells with tissue could provide a more complete picture of 
the possible in-man response to monoclonal antibodies (mAbs), whereas animal 
studies would only provide a partial insight to the drug response (Stebbings et al. 
2013). However, routinely sourcing human skin and blood from matching donors for 
testing is a challenge, due to both the limited size of samples that can be obtained from 
donors and varying availability of healthy volunteers. Samples must be taken through 
minimally invasive procedures and be within the size/volume guidelines outlined by 
ethical approval. Small samples restrict testing to a small number of drugs or chemicals 
and therefore are not ideal for testing panels of drug candidates on a large industrial 
scale. 
To date there have been many advancements in the field of tissue engineering, 
especially when engineering (three-dimensional) 3D human skin equivalents for both 
clinical and research applications (Ali et al. 2015; Hill et al. 2015). Therefore, a potential 
solution to small sample sizes could be to isolate skin cells from donor biopsies and 
use the cells to engineer 3D skin equivalents allowing more tests to be performed per 
donor. Alcyomics have previously fabricated skin equivalents in a 6-well format 
referred to as Skimune3D® however this format was too large for high-throughput 
testing and required large cell numbers. Therefore, only a small number of skin 
equivalents per donor could be produced. It was recognised that this technology would 
greatly benefit from a reduction in format, by minimising the overall size of the 3D skin 
equivalents and maximising the number of equivalents per donor to develop a high-
throughput platform for preclinical in-vitro testing. 
In the years since Wilson and Boland’s first cell dispensing bioprinter the field of 
bioprinting has very much grown beyond its infancy (Wilson and Boland 2003). The 
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cross-disciplinary nature of bioprinting has given rise to collaborations from the fields 
of cellular biology, medicine, materials science, physics and engineering to develop 
alternative techniques and materials to print scaffolds and cells for various functions 
(Murphy and Atala 2014). Regenerative medicine has inspired the bioprinting and 
transplantation of cartilage substitutes, vascular grafts, an airway splint and skin 
constructs (Cui et al. 2012; Marga et al. 2012; Michael et al. 2013; Zopf et al. 2013). 
While there is a large focus on developing 3D structures and tissues for in-vivo 
applications there are yet to be significant steps made in the development of bioprinted 
high-throughput 3D tissue equivalents for in-vitro applications, namely drug testing 
(Mazzocchi, Soker, and Skardal 2019). Reducing the size of the Skimune3D® skin 
equivalents could increase the feasibility of bioprinting 3D skin equivalents which are 
both representative of tissue in-vivo and can be suitable for in-vitro assays. The 
automation of bioprinting can allow for the high-throughput deposition of cells which 
would be ideal for the biofabrication of tissue equivalents on a large scale. 
Consequently, the bioprinted Skimune3D® skin equivalent could be suitable for 
assessing the immunotoxicity of biologics and could be adapted for other in-vitro 
applications. This would be a novel contribution to both the pharmaceutical industry 
and the field of biofabrication. 
As with many high-throughput processes some element of automation would be 
advantageous, for Skimune3D® the bioprinting of skin equivalents would provide a 
manufacturing platform that would be scalable to industrial needs. While bioprinting 
and the concept of in-vitro therapeutic antibody testing are not novel concepts, the 
unique combination of the Skimune3D® platform and high-throughput bioprinting for 
therapeutic antibody testing would be a novel contribution to science and to the 
pharmaceutical industry. This novel approach to preclinical testing may provide 
industry with a fully autologous human system to detect immunotoxic events often 
related to therapeutic mAb treatments. 
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1.2 Literature Review 
1.2.1 The Structure of Human Skin 
In humans, skin is the largest organ with a range of functions such as protection, 
sensation, thermoregulation, excretion and absorption (Proksch, Brandner, and 
Jensen 2008). Skin consists of three main layers; epidermis, dermis and hypodermis 
(subcutaneous tissue) as is illustrated in Figure 1.1 (Kanitakis 2002). 
 
The epidermis is the outermost layer of the skin and has a stratified structure formed 
by four sub layers: the basal strata, stratum spinosum, stratum granulosum and the 
stratum corneum (Figure 1.2). The epidermis also contains four cell types; Merkel cells, 
Langerhans cells, melanocytes and keratinocytes, the latter are the most abundant 
cells in the epidermis (Wong et al. 2016). Proliferative undifferentiated keratinocytes 
are found in the basal strata of the epidermis. These cells provide a self-renewing layer 
for the epidermis to replace cells lost from the upper strata. As the healthy 
keratinocytes begin to terminally differentiate into corneocytes they migrate from the 
basal layer progressing superficially through the strata towards the stratum corneum. 
Figure 1.1. The structure of human skin. Skin typically features three layers; 
epidermis, dermis and hypodermis. Human skin usually contains hair follicles, nerves, 





As the cells superficially migrate the formation of tight junction complexes aids cell-cell 
adhesion and allows keratinocytes to form an effective cell barrier (Kirschner and 
Brandner 2012). Once the keratinocytes reach the stratum granulosum cell death 
begins to occur as the lamellar bodies release lipids and cells become filled with 
keratohyalin precursors which promote the development of a cornified envelope. The 
keratohyalin granules become progressively more visible as the cells begin to 
differentiate with the granules being most noticeable in the stratum granulosum 
resulting in the granular appearance in histology.  
 
Throughout the epidermis keratinocytes express a range of cellular and cytoskeletal 
markers. Cytokeratin-5 (CK5), CK14 and CK15 are expressed by undifferentiated 
keratinocytes in the basal layer of the epidermis while CK1, CK2 and CK10 are 
expressed by differentiating cells which are found in the spinous and granular strata 
(Moll, Divo, and Langbein 2008). The stratum corneum contains structural proteins 
such as involucrin and loricrin (Candi, Schmidt, and Melino 2005; Nemes and Steinert 
1999). These markers are routinely used to detect differentiation of keratinocytes. 
Beneath the epidermis lies the basement membrane which separates the dermis and 
the epidermis. The basement membrane mainly comprises of laminins and collagen 




(loricrin and involucrin) 
Stratum Granulosum 
(CK10, CK1 involucrin) 
Stratum Spinosum (CK10, CK1 
and involucrin) 
Stratum Basale (CK14 
and CK5) 
Basement membrane 
(collagen IV and VI) 
Figure 1.2. The sublayers of the epidermis and stratified markers. The 
epidermis contains 4 strata each with a different range of biomarkers. The 




the basement membrane collagen VII facilitates anchoring of the basement membrane 
to the dermis via looping structures which interweave and adhere to dermal collagen I 
(Villone et al. 2008). This improves functional properties and structural strength of skin 
(McMillan, Akiyama, and Shimizu 2003).  
The dermis is a thicker layer of tissue beneath the dermal-epidermal junction which 
supports the epidermis and has sublayers. The dermis contains connective tissues 
such as collagen, elastin and fibronectin (Krieg and Aumailley 2011). Such 
extracellular matrix proteins can define the elasticity and strength of the dermis 
(Bruckner 2010). The uppermost layer of the dermis is the papillary dermis located 
close to the basement membrane, this region contains a high population of dermal 
fibroblasts within a compact network of small collagen fibres (Rognoni and Watt 2018). 
The reticular dermis is the larger layer of dermis found beneath the papillary dermis. 
The reticular dermis contains thicker extracellular matrix (ECM) particularly larger 
reticular collagen fibres and is less densely populated by fibroblasts (Rognoni and Watt 
2018). Under the reticular dermis is the subcutaneous hypodermis which contains 
adipocytes filled with lipid (Rognoni and Watt 2018). 
1.2.2 The Historical Development of Skin Equivalents  
Skin explants, also known as histocultures, are often used to replicate in-vivo 
environments. While skin explants have many uses there are also several limitations 
(Hoffman 1991; Li et al. 1992; Li, Margolis, and Hoffman 1991). Skin explants are 
restricted in both availability and size of the sample. Such restrictions increase the 
appeal of 3D human skin equivalents (HSEs). HSEs have been developed and refined 
over many years as an alternative to two-dimensional (2D) systems, skin explants, and 
animal models. However, to develop HSEs which are physiologically representative of 
human skin the isolation and culture of skin cells from human skin is necessary.  
In 1975 Rheinwald and Green reported the successful in-vitro cultivation of 
keratinocyte colonies from a single founder keratinocyte by using lethally irradiated 
3T3 mouse fibroblasts as a layer of feeder cells (Rheinwald and Green 1975). It was 
reported that the isolated keratinocytes could successfully form colonies and ultimately 
form a stratified squamous epithelium (Rheinwald and Green 1975). The addition of 
hydrocortisone to the culture media was reported to improve cell morphology and 
slightly increase proliferation, however Rheinwald and Green found the culture lifetime 
of keratinocytes to vary between 20-50 cell generations (Rheinwald and Green 1975). 
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These findings provided a foundation for future in-vitro studies to further improve 
keratinocyte culture techniques. Freeman et al produced a method of using 
decellularised and de-epidermised dermis (DED) derived from pigs to culture 
keratinocytes (Freeman et al. 1976). The DED acted as a substrate for human skin 
samples. Though only human keratinocytes adhered to the decellularised pig dermis, 
basal and granular cell layers were also reported indicating a degree of epidermal 
keratinocyte differentiation. As only keratinocytes adhered to the DED the resulting 
model was more representative of a reconstituted epidermis equivalent than a full 
thickness skin model. Lillie et al made use of culture at an air-liquid interphase (ALI) 
with a collagen raft to culture keratinocytes (Lillie, MacCallum, and Jepsen 1980). The 
ALI allowed the upper epidermis to be exposed to air, thereby replicating in-vitro 
conditions. The keratinocytes undergoing terminal differentiation were observed with 
pyknotic nuclei and organelle debris. The high degree of tissue organisation was 
attributed to the use of an ALI. Pruniéras et al used ALI with a human DED to culture 
and differentiate keratinocytes (Prunieras, Regnier, and Woodley 1983). Pruniéras et 
al identified differentiation through morphological markers however the expression of 
keratin precursors was limited (Prunieras, Regnier, and Woodley 1983). The limited 
expression of the differential keratins was attributed to the filtering qualities of the 
dermal substrate since the cells need to be fed from below at ALI (Prunieras, Regnier, 
and Woodley 1983). This study highlighted the need for an appropriate dermis to 
achieve a good range of keratin expression. Hull et al demonstrated that dermal 
equivalents could also be seeded with dermal fibroblasts by using a collagen lattice 
populated with cells (Hull et al. 1983). In addition to DEDs, inert acetate cellulose filters 
and non-biological polycarbonate films have been shown to act as acellular dermal 
substrates (Rosdy and Clauss 1990). Langerhan cells and melanocytes have also 
been integrated into the epidermis in attempts to further replicate the in-vivo 
environment of human skin resulting in more physiologically representative models 
(Regnier et al. 1998; Regnier et al. 1997). El-Ghalbzouri et al investigated the impact 
of fibroblasts on epidermal formation by preparing collagen matrices with increasing 
numbers of fibroblasts, upon which keratinocytes where seeded (el-Ghalbzouri et al. 
2002; Hull et al. 1983). The findings showed that in the presence of fibroblasts, 
keratinocyte proliferation, differentiation and epidermal stratification improved. In the 
presence of fibroblasts the formation of the basement membrane at the dermal 
epidermal junction also improved (el-Ghalbzouri et al. 2002; Wong, McGrath, and 
Navsaria 2007). Such studies demonstrate the advantages of using a fibroblast 
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populated dermal equivalents when reconstructing the epidermis, however the material 
used for the dermal scaffold does require good consideration (Prunieras, Regnier, and 
Woodley 1983). 
The increasing interest in 3D scaffolds has resulted in the development of both natural 
and synthetic biocompatible materials. There are a variety of biodegradable hydrogels 
and polymers such as polylactic acid and polyglycolic acid for tissue engineering 
(Mikos et al. 1993; Park et al. 2005; Sims et al. 1998; Yu, Dillon, and Bellamkonda 
1999). While biodegradable scaffolds may be desirable for in-vivo applications, the use 
of biodegradable scaffolds in-vitro for HSEs could restrict model development as the 
growth of a dermal equivalent and epidermal differentiation is a lengthy process. 
Scaffold degradation could affect the exposure of the epidermis to the ALI which in turn 
can restrict maturation of the epidermis by denying optimal culture conditions. 
Therefore, the use of an inert scaffold would be appropriate for the fabrication of 
autologous HSEs for in-vitro early phase drug testing. Haymen et al developed a highly 
porous polystyrene scaffold which was redeveloped to be compatible with general 
everyday use tissue culture plastic (Bokhari et al. 2007; Hayman et al. 2004, 2005). 
This porous polystyrene scaffold was later used by Hill et al to fabricate full-thickness 
HSEs to model the melanoma infiltration of the dermis (Hill et al. 2015). Hill et al used 
primary fibroblasts and keratinocytes to develop HSEs with a fully stratified epidermis 
containing terminally differentiated keratinocytes and a dermal equivalent populated 
with fibroblast which synthesise ECM (Hill et al. 2015). The study by Hill et al was an 
example of the usefulness of a scaffold that could not only accommodate fibroblasts 
but be porous enough to allow adequate diffusion of oxygen and nutrients encouraging 
proliferation of cells and ECM production. The fibroblasts and ECM would then act as 
a dermis capable of supporting keratinocytes seeded onto the surface of the dermal 
equivalent. The keratinocytes were cultured at ALI to form a stratified epidermis, 
resulting in a full-thickness skin equivalent. Originally designed as an investigative tool 
to understand the early stages of melanoma invasion this fully humanised system was 
later patented by Alcyomics Ltd with a view to adapting the HSE into an autologous 
system suitable for immunotoxicity. 
While there are other competitors in the market for in-vitro HSEs (Table 1.1) for 
toxicology and pharmacology testing it seems there is currently a gap in the market for 
autologous, full-thickness HSEs with donor matched peripheral blood monocytes 
(PBMCs) for in-vitro immunotoxicology. Commercially available HSEs are either 
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reconstituted human epidermis (RHE) models where human keratinocytes are cultured 
on a synthetic polymeric scaffold to produce a stratified epidermis or full-thickness 
HSEs where keratinocytes are cultured and differentiated on a fibroblast populated 
dermal equivalent. A RHE is developed by seeding and submerging keratinocytes on 
a porous transwell membrane for several days. After submerged culture the RHE is 
raised to ALI to allow the keratinocytes to differentiate and form a stratified epidermis. 
Using standard culture techniques there are now a range of commercial RHE 
equivalents available such as EpiDerm™ from MatTek Corporation, SkinEthic™ and 
EpiSkin™ from EpiSkin (which is a subsidiary of the L’Oréal group) and EpiCs® from 
CellSytems GmbH. Each of these RHE equivalents (shown in Figure 1.3) have been 
validated in assays for sensitisation and irritation using the Organisation for Economic 
Co-operation and Development (OECD) guidelines 439 and 432 (Andres et al. 2017; 
Cottrez et al. 2015; Cottrez et al. 2016; Gibbs et al. 2013; Saito et al. 2013). The 
EpiSkin™ in-vitro model was used by Cottrez et al to develop the SENS-IS assay which 
investigated changes in gene expression of the SENS-IS gene subset in response to 
sensitisation after exposure to chemicals (Cottrez et al. 2015; Cottrez et al. 2016). 
Cottrez et al showed that the use of the RHE model with the SENS-IS assay was 100% 
reproducible between 3 laboratories with 150 chemicals correctly predicting sensitivity 
with 95.8% accuracy and 96.5% specificity (Cottrez et al. 2016). When comparing 
SENS-IS assay data to literature complied by Basketter et al the SENS-IS assay 
showed 92.6%, and 90.6% compared to the mouse local lymph node assay (MLLNA) 
data and human data respectively (Basketter et al. 2014; Cottrez et al. 2016). MatTek 
EpiDerm™ was used by Saito et al to develop another assay named EpiSensA assay 
which is also a gene analysis assay (Saito et al. 2013). Saito et al used a smaller panel 
of 5 genes and 16 chemicals which still reported high accuracy but this was lower than 
what was reported by Cottrez et al, though the SENS-IS studies did use a much larger 
panel of genes and chemicals. (Cottrez et al. 2016; Saito et al. 2013). Saito et al later 
used the LabCyte EPI-MODEL from Japan tissue Engineering Co. Ltd, a subsidiary of 
the Fujifilm group, which was tested along with the EpiSensA assay using a total of 72 
chemicals (Saito et al. 2017). Results showed that with the use of a RHE the sensitivity, 
specificity, and accuracy of lipophilic chemicals was 96, 75, and 88% respectively 
(Saito et al. 2017). According to Saito et al this data was more accurate than when 
validated using in-vitro 2D culture based tests for example the human line cell 
activation test (hCAT) and the KeratinoSens™ assay (Saito et al. 2017). A combination 
of EpiCS®, SkinEthic™, EpiDerm™ and an in house RHE equivalent were used by 
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Gibbs et al to identify an increase in production and release of interleukin-18 (IL-18) in 
response to exposure to sensitisers (Gibbs et al. 2013). The stated accuracy of the IL-
18 assay was >95% (Gibbs et al. 2013). It is important to note that current commercial 
RHE equivalents only contain one cell type, keratinocytes. However, including 
additional cell types found within the epidermis may not be complex. The lack of a 
dermal compartment with fibroblasts means that there is no in-vitro communication 
between fibroblasts and keratinocytes which can influence inflammatory cytokine 
response in assays (Spiekstra et al. 2007).  Additionally, the use of RHEs are currently 










Figure 1.3. Representative histology images of commercially available 
reconstructed human epidermis (RHE) models (A-D) and full-thickness skin models 
(E-G). (A) EpiDerm™, (B) SkinEthic™, (C) EpiSkin™, (D) EpiCs® (E) EpidermFT™, 
(F) Phenion® FT, (G) StrataTest®. Images adapted from www.mattek.com, 
https://www.phenion.com, www.episkin.com, www.reconstructed-human-
epidermis.com, Rasmussen et al 2010. 
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Currently there a range of commercially available skin equivalents (Table 1.1) used for 
various applications. However as of yet there are no 3D skin equivalents available to 
the pharmaceutical industry that could be exploited to assess the immunotoxicity of 
biologics. The main commercially available full-thickness HSEs are EpidermFT™ from 
the MatTek Corporation, the Phenion® FT model from Phenion of the Henkel Company 
and StrataTest® from the Stratatech Corporation. EpidermFT™ has been used to 
investigate the irritation potential of aliphatic hydrocarbons in-vitro (Mallampati et al. 
2010). Mallampati et al incubated the EpidermFT™ equivalents with hydrocarbons of 
interest and measured the release of pro-inflammatory cytokines IL-1α, IL-6 and IL-8 
and compared the results to murine experiments performed in-vivo (Mallampati et al. 
2010). The study showed that the irritation profile and the expression of cytokines 
increased with heavier hydrocarbons much like the response that was seen in-vivo 
(Mallampati et al. 2010). The barrier property of the Phenion® full-thickness was 
compared with ex-vivo pig skin (Ackermann et al. 2010). The ex-vivo pig skin was 
shown to be less permeable than the Phenion® full-thickness skin equivalents, which 
was shown to be more permeable than RHE equivalents previously tested (Ackermann 
et al. 2010; Schafer-Korting et al. 2008). Rasmussen et al exposed the StrataTest® full-
thickness skin equivalents to chemical irritants, ultra-violet (UV) irradiation and 
environmental stress in addition to assessing barrier function (Rasmussen et al. 2010). 
The barrier function of the HSEs were found to be comparable to physiological human 
skin (Rasmussen et al. 2010). It was shown the release of reactive oxygen species 
(ROS) could be detected in HSEs exposed to environmental stress but this increase 
in ROS could be somewhat prevented by the pre-treatment of the HSEs with the 
antioxidant parthenolide-depleted feverfew extract (Rasmussen et al. 2010). An 
increase in cytokines IL-1α and IL-1RA were detected in response to UV irradiation 
which could be prevented by the application of sunscreen prior to exposure 
(Rasmussen et al. 2010). The Vrije Universiteit Medical Centre used in-house HSEs to 
investigate the level of cytokines that initiate immune cell infiltration (Spiekstra et al. 
2005). The data from this study suggested that the skin cells secreted IL-1α and 
Tumour necrosis factor alpha (TNF-α) in response to irritants and could trigger immune 
cell infiltration of the HSEs (Spiekstra et al. 2005). Evidently currently available 
commercial HSEs can serve a variety of functions however due to the use of non-
human ECM the HSE are not fully human or autologous. The use of the commercially 
available HSEs for testing of barrier function, sensitisers and allergens, suggests that 
there is a gap in the market for a commercial HSE that could be used for screening of 
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biologics at the early stages of drug development. 
Table 1.1. Currently available commercial skin equivalents, including type of 




Equivalent type Manufacturer Cell types 












































1.2.3 Preclinical Safety Testing and the Cost of Failure  
Historically regulatory preclinical safety testing has relied upon the use of various 
species for in vivo studies. Such species include rodents (mice and rats), and non-
rodents (dogs, pigs and nonhuman primates (NHPs) (Prior, Sewell, and Stewart 2017). 
NHPs are commonly used as tools for predicting adverse events of molecules, 
particularly large molecules like monoclonal antibodies (mAbs) in preclinical testing 
14 
 
(Bode and Starck-Lantova 2018). NHPs are in high demand as they are generally 
considered to be the most appropriate species for safety testing of biologics, as mAbs 
are highly specific to human targets and the expression of targets and target function 
in NHPs are similar to humans (Baumann et al. 2014; Bode and Starck-Lantova 2018). 
This results in NHPs demonstrating the anticipated pharmacological effect of the mAb, 
more so than other species with the exception of the minipig and transgenic murine 
models in some cases (Baumann et al. 2014; Blaich et al. 2016). Despite this there are 
disadvantages to NHPs. NHP studies are costly, can take months to see through and 
there is also the public scrutiny associated with in-vivo models (Bode and Starck-
Lantova 2018). When Van Meer et al analysed the drug registration profiles of mAbs 
registered in the European Union the data showed that in only 59% of cases the 
immunogenicity of mAbs between NHPs and humans were comparable (van Meer et 
al. 2013). Furthermore the type of antidrug antibody (ADA) response differed between 
NHPs and humans in 59% of the cases (van Meer et al. 2013). The ADAs formed were 
responsible for the neutralisation or clearance of the mAbs (van Meer et al. 2013). The 
disparity in responses between NHPs and human studies highlights exactly how 
uninformative animal studies can be when predicting adverse immune responses. In 
recent years there has been an increase in the use of the minipig model for preclinical 
safety testing (Ganderup et al. 2012). Minipig models can be used as cheaper short 
term alternatives to NHPs for investigating biologics that interact with the immune 
system as the immune system of minipigs are more comparable to that of humans than 
dog models (Baumann et al. 2014; Bode et al. 2010). Although in terms of genetic 
homology minipigs are not more closely related to humans than NHPs due to the closer 
genetic ancestry between humans and NHPs. As established the use of animal models 
in pre-clinical test are not fool proof, and failure to identify unsuitable drug candidates 
at this stage can have severe financial consequences. 
Overall, the preclinical safety testing process for screening drugs using in-vitro and in-
vivo studies is costly to drug developers. Such costs mandate the importance of early 
stage identification of adverse drug candidates to limit both the cost and chance of 
failure. An in depth study by Wong et al  analysed over 406,038 entries of clinical trial 
data for 21,143 compounds in the US (Wong, Siah, and Lo 2018). Wong et al used the 
clinical trial data to develop an algorithm to compute the probability of success (POS). 
Overall Wong et al estimated a POS of 11.2% in 2005 which steadily declined to 5.2% 
in 2013, after which the estimated POS increased to 6.7% (2014) and 13.8% (2016) 
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(Wong, Siah, and Lo 2018). Wong et al proposed that the improved POS may be 
attributed to the use of biomarkers becoming more common allowing drug developers 
to target specific patients for more favourable outcomes (Wong, Siah, and Lo 2018). 
Another suggestion from Wong et al was that this period involved a wave of medical 
breakthroughs, citing that Nivolumab (Bristol-Myers Squibb Company) was approved 
on five separate occasions in multiple markets in less than one year (Wong, Siah, and 
Lo 2018). Another possible explanation suggested by Smietana et al was that 
pharmaceutical companies implemented changes to the research and development 
process for drug candidates (Smietana, Siatkowski, and Moller 2016; Wong, Siah, and 
Lo 2018). In the sharp decline of clinical success rates (2007-2010) many large-scale 
drug developers underwent changes followed by more selective development pipeline 
processes (Smietana, Siatkowski, and Moller 2016). Smietana et al suggested that the 
changes to research and development improved overall POS indicating that more 
robust early stage identification of poor drug candidates could influence the POS of a 
drug (Smietana, Siatkowski, and Moller 2016). Drug development is a lengthy process, 
failure to identify poor drug candidates early enough can be incredibly costly to 
pharmaceutical companies. Since 1990 there has been an increase in investment by 
pharmaceutical companies to investigate drug candidates, though this has not resulted 
in an increase in output (Pammolli, Magazzini, and Riccaboni 2011). DiMasi et al 
estimated a pre-tax, pre-approval out-of-pocket cost of $1.5 billion (2019 dollars) and 
a capitalised cost of $2.9 billion (2019 dollars) for new drugs (DiMasi, Grabowski, and 
Hansen 2016). DiMasi et al suggested that costs were largely influenced by the high 
failure rates of drug testing in humans (DiMasi, Grabowski, and Hansen 2016). 
Therefore, the availability of human skin equivalents for predicting adverse events in-
vitro could potentially be beneficial to the drug development process. The use of 
bioprinting to scale up testing could be of use for analysis of early drug candidates. By 
testing immunotoxic properties of biologics early in the pipeline process drug 
developers can decide which molecule should not proceed to the next stage of 
development, thereby saving time and money.  
1.2.4 Bioprinting Technology 
Advances in 3D printing technology in recent years have led to the development of 
machines and materials which are more applicable to biomedical applications. 
Biomedical applications range from the printing of implants, tissue scaffolds to the 
deposition of cells (Murphy and Atala 2014). The addition of cells intensifies the 
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complexity of the printing process compared to standard 3D printing. Factors such as 
the printing process, cell types, printing stress on cell viability and the biocompatibility 
of selected materials and inks all need to be considered (Blaeser et al. 2016; Murphy 
and Atala 2014). This technology can allow the geometric and compositional 
complexity of tissue to be replicated through developing 3D structures with more than 
one cell type and in a specific organisation. The three most popular printing processes 
are inkjet, microextrusion and laser assisted bioprinting (Figure 1.4).  
Inkjet bioprinters deposit droplets on demand (DOD) to a desired location. Inkjet 
printers are normally driven by two different mechanisms, either a thermal actuator or 
a piezoelectric actuator. Thermal inkjet printers use a heating filament within the print 
head to quickly vaporise some ink and form a bubble. The formation of an air bubble 
causes changes in pressure which is enough to overcome the surface tension of the 
ink and force a droplet to be ejected from the nozzle. While it has been reported that 
the thermal process is not significantly detrimental to cell viability and functionality (Xu 
et al. 2006; Xu et al. 2005) the risk of thermal stress impacting cells is additional to 
shear forces during printing.  
Piezoelectric systems use a material within the printhead which changes shape when 
a voltage is applied. The rapid deflection of the piezoelectric material causes an 
acoustic wave inside the printhead. This pulse in the printhead causes a change in 
pressure triggering ink to be ejected from the nozzle orifice forming a droplet (Fang et 
al. 2012). As this pulse can be manipulated by changing the voltage applied to the 
piezoelectric material, piezoelectric printers offer more control over droplet uniformity 
and directionality than thermal systems. Voltage waveforms and the vibration 
Figure 1.4. Three common bioprinting methods. (A) Thermal inkjet systems use 
heat to cause shifts in pressure resulting in a droplet while piezoelectric systems 
depend on the sudden deflection of the actuator to trigger the formation of a droplet. 
(B) Extrusion processes require constant pneumatic or mechanical back pressure to 
extrude chains of ink. (C) Laser based printers require an absorbing substrate to 




frequency (Hz) are used to control the pulse. To optimise the droplet formation of inkjet 
printing the pulse width (Pw) and amplitude (Pa) must also be optimised (Derby 2010) 
(Figure 1.5). The inkjet systems are generally widely available and offer good 
resolution but are not without flaws. Thermal systems include the risk of exposing the 
inks and components to thermal stress (Murphy and Atala 2014) and the heating 
filaments may need to be replaced over time due to possible material deposits reducing 
the effectiveness of the filament. Droplet deposition and size in inkjet process are 
impacted by properties of the ink such as viscosity and surface tension making 
deposition of high viscosity ink challenging. For this reason inkjet bioprinters use low 
viscosity inks such as cells suspended in culture media (Blaeser et al. 2016; Murphy 
and Atala 2014), although it has been demonstrated that alginate based inks can also 
be printed using inkjet systems (Negro, Cherbuin, and Lutolf 2018). Inkjets usually 
have a volume range of 1-100pL (Derby 2010). Therefore, a single inkjet may not be 
suitable for high-throughput processing but may be ideal for the deposition of lower cell 
densities in low viscosity inks. The advantages and disadvantages of inkjet printing are 
summarised in Table 1.2, page 22. 
  
Figure 1.5. An example of jetting pulse waveform labelled with pulse width (pw) 
and amplitude (pa). Trapezoid waveforms are commonly used during inkjet printing. 
Microextrusion is a similar process to many commercially available desktop 3D 
printers. Pneumatic and mechanical (piston and screw) mechanisms are used to 
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extrude material through the nozzle in microextrusion (Figure 1.4b). These printing 
mechanisms allow close control of the flow of material, making the process ideal for 
the deposition of hydrogels and high cell densities (Murphy and Atala 2014). It is worth 
noting that the viability of cells post printing can be lower in comparison to other printing 
methods due to shear forces when extruding the high viscosity inks as shown in Figure 
1.6 (Panwar and Tan 2016). Larger nozzle sizes and lower pressures may be used to 
maintain cell viability at the cost of resolution and print speed. The advantages and 
disadvantages of microextrusion processes are summarised in Table 1.2, page 22. 
Figure 1.6. Distribution of pressure and shear stress during microextrusion. As 
viscous cell laden inks are extruded there is an increase in pressure at the tip orifice. 
Cells close to the walls of the ink reservoir are exposed to more shear stress than those 
in the centre. Image from Panwar and Tan 2016. 
Laser-assisted bioprinting (LABP) was developed using the process of laser-induced 
forward transfer (LIFT) for DOD deposition. LIFT printing uses a laser to form a bubble 
between an energy absorbing layer and the bio-ink (Figure 1.4). The changes in 
pressure from the bubble cause a droplet of material to form. This process is also 
suitable for DOD deposition of bio-inks with high cells densities with cell high viability 
post printing (Koch et al. 2010). However low viscosity bio-inks with poor adhesive 
properties cannot be processed using LABP. As a result, LABP bioprinters are 
restricted to high viscosity bio-inks such as cross-linked hydrogels or gel precursors 
(Michael et al. 2013; Murphy and Atala 2014). The advantages and disadvantages of 
LABP processes are summarised in Table 1.2, page 22. 
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Microvalve based bioprinting is another DOD process which typically involves the use 
of a gas regulator which provides pneumatic pressure to the print head. Within the 
microvalve a solenoid coil is used to lift a plunger that blocks the nozzle orifice (Figure 
1.7). When a voltage is applied to the solenoid coil a magnetic field in the coil pulls the 
plunger away from the nozzle, opening the nozzle orifice. Once the nozzle orifice has 
been opened the pneumatic pressure is used to deposit the ink. When enough 
pressure is applied to overcome ink surface tension and viscosity at the nozzle orifice 
the ink is ejected forming a droplet. At the end of the waveform there is no voltage 
applied to the solenoid and so the plunger drops and blocks the nozzle orifice again, 
this is one actuation cycle resulting in one droplet. Ink deposition is influenced by 
factors such as ink viscosity, ink surface tension, the applied pressure, nozzle diameter 
and the duration that the valve is open (Lee et al. 2009). Solenoid microvalves can 
deposit cells with high viability (Lee et al. 2009). The droplet size of solenoid 
microvalves ranges in the nanolitres allowing valves to deposit cells in high densities 
which would be ideal for high-throughput fabrication of tissue models (Faulkner-Jones 
et al. 2015). As microvalves can handle a wide range of pneumatic pressure, 
microvalve based bioprinters can dispense low viscosity inks such as cells suspended 
in media and high viscosity inks such as cell-laden hydrogel precursors(Faulkner-
Jones et al. 2013; Lee et al. 2009; Okubo et al. 2019). The advantages and 




In DOD processes cell laden bio-inks can act as unstable colloid suspensions (Figure 
1.8). Cells in suspension usually form cell-cell adhesions and sediment over time, 
resulting in the formation of flocs. Flocs are aggregated particles in suspension. As 
flocs form the cells are no longer equally distributed within the bio-ink. An uneven 
suspension of cells within the bio-ink can impact the homogeneity of cells per droplet 
and block printheads therefore disrupting prints. As agitation systems for maintaining 
cell suspensions in bioprinters are not widely available some studies have investigated 
methods of preventing printing cell-cell adhesions. Ribeiro et al investigated the use of 
a temporarily speckled coating for cells using a polycation to restrict cell-cell adhesion 
(Ribeiro et al. 2017). Poly-L-lysine (PLL) was used to apply a speckled coating to cells 
to prevent cell agglomeration. Ribeiro et al observed that cells ingested the PLL and 
metabolised the polymer before returning to phenotypically normal behaviour. Ng et al 
used polyvinylpyrrolidone (PVP) macromolecules to develop bio-inks in an attempt to 
improve the printability of cell suspensions (Ng, Yeong, and Naing 2017). It was 
reported that the PVP based bio-inks were able to mitigate the cell adhesion and 
sedimentation over a period of 30 minutes (Ng, Yeong, and Naing 2017). 
Figure 1.7. The opening a closing of a solenoid valve. When no voltage is applied 
to the solenoid the valve is in a closed state. The 24v spike opens the valves as 
quickly as possible and the dwell voltage of 5v holds the valve open without 
generating too much heat. Once the valve is open a positive back pressure pushes 
ink through the nozzle orifice. When the voltage is no longer applied to the solenoid 
the plunger drops and blocks the nozzle orifice again. This is one actuation cycle 
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Stable colloid  Unstable colloid  
Figure 1.8. Cells in suspension act as colloidal suspensions. In DOD systems 
suspensions of cells often behave as colloidal suspensions. When cells are initially 
suspended in even distribution they are stable colloids. The cells often form adherences 
to one another and naturally sediment over time. The clumps which form and sediment 
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1.2.5 Bioprinting of Skin 
While the development of 3D skin equivalents through conventional tissue engineering 
techniques has been well established there have been attempts to bioprint skin with 
varying success due to the materials and cells used. Lee et al used a custom built 
microvalve system to deposit layers of primary human dermal fibroblasts and 
keratinocytes within a type 1 rat tail collagen gel scaffold (Lee et al. 2009). Collagen 
gel precursors were printed and partially cross-linked using nebulised sodium 
bicarbonate as the crosslinking agent. Then cells were printed into the partially cross-
linked gel causing the cells to be embedded within the gel. The partially cross-linked 
gel was further cross-linked with nebulised sodium bicarbonate to provide a foundation 
for the next layer. This method of embedding cells into gels showed no significant loss 
in cell viability and no changes in cell morphology. This work was further built upon 
using the same bioprinting system and crosslinking mechanism for collagen gel 
precursors to print HFF-1 fibroblasts and HaCaT keratinocytes (Lee et al. 2014). The 
cell laden gel constructs were printed onto a transwell membrane and cultured at ALI. 
Lee et al did not report any significant loss in cell viability, with viability decreasing to 
84-89% at lower cell densities (0.5-0.75x106/mL) and larger droplet spacing of 400–
750 mm (Lee et al. 2014). These constructs were submerged in media for 4-8 days 
and then raised to an ALI for 14 days. The histology of the printed tissue can be seen 
in Figure 1.9. The dermis appeared to be sparsely populated despite the seeding of 
2.3x105 fibroblasts in contrast to 1.4x105 keratinocytes. The lack of stratification is 
noticeable in Figure 1.9 potentially due to the use of HaCaT cells entrapped in a gel 




LABP technology was used by Koch et al to sequentially print layers of NIH-3T3 Swiss 
albino fibroblasts and HaCaT cells suspended in a rat tail type 1 collagen gel (Koch et 
al. 2012). An acellular dermal substitute (MatridermTM) was used as the substrate. The 
bioprinted gels were fabricated in two layers. The first layer (lower layer) was 
constructed with 20 sub-layers of fibroblasts and the upper layers were made of 20 
sublayers of keratinocytes. In total 1.5x106 fibrobolasts were printed in the dermal layer 
and 1.5x106 keratincoytes were printed into the epidermal layer. The bioprinted 
constructs were printed and submerged in culture media for 10 days before being 
harvested. Figure 1.10 shows the histology of the bioprinted constructs after 10 days 
in culture. While it is easy to differentiate between what is referred to as the dermis and 
epidermis from Figure 1.10 there is little development of the epidermal layer much like 
the work of Lee et al (Lee et al. 2014). Later Michael et al used the above LABP system 
to sequentially print 20 layers NIH-3T3 fibroblasts and 20 layers of HaCaT 
keratinocytes onto MatridermTM sheets (Michael et al. 2013). The prints were 
submerged over night before being cultured at an ALI for up to 11 days. Histological 
sections of harvested constructs are shown in Figure 1.11. Figure 1.11 shows that the 




Figure 1.9. Histology of skin constructs bioprinted by Lee et al. (A) H&E staining 
of tissue constructs. (B) N-cadherin staining of construct showing some degree of 




Figure 1.10. Histology of cell-gel constructs bioprinted using LABP. (A) Sections 
of the bioprinted constructs 10 days after printing. Haematoxylin-eosin staining of bi-
layered construct Immunoperoxidase staining of cytokeratin 14 in reddish-brown of bi-
layered construct (B). Scale bars: 50µm. Adapted from Koch et al 2012. 
Figure 1.11 Mason trichrome staining of LABP cell-gel constructs cultured at 
ALI. All constructs were incubated submerged overnight. (A) construct incubated 
overnight, defined as day 0. (B) Construct harvested at day 5 ALI. (C) Construct 
harvested at day 11 ALI. Scale bars: 100µm. Adapted from Michael et al 2013.  
The use of cell lines in the above studies do provide homogeneity between prints, 
however using primary human fibroblasts and human keratinocytes could help produce 
bioprinted skin equivalents which more accurately represent the structure of human 
skin in-vivo. A relatively simple microextrusion based system was developed by Cubo 
et al by modifying an open source Reprap Printrbot (Cubo et al. 2016). The Printrbot 
was customised to use piston based microextrusion and a mixing cartridge to extrude 
gels. Three separate dispensers were used to mix human fibroblasts, human plasma 
and CaCl2 into the mixing cartridge above the nozzle prior to printing.  The human 
fibrin-fibroblast matrix was dispensed onto transwell membranes. Following cross-
linking of the dermal layer at 37oc, a suspension of human keratinocytes was seeded 
onto the dermal layer, incubated overnight, and cultured at the ALI for 17 days. 
Histological staining of the in-vitro skin equivalents (Figure 1.12) showed some 
delamination of the extra-cellular matrix in the dermis, but the epidermis was well 




Figure 1.12. H/E staining of skin equivalents fabricated by microextrusion. (A) 
‘Handmade’ skin. (B) Bioprinted skin equivalent. Ep and De refers to the dermis and 
epidermis, respectively. The dotted line indicates the basal membrane Scale bars: 100 
μm. Image from Cubo et al 2016. 
Researchers from Singapore developed pigmented equivalents by using microvalves 
to print fibroblast-laden collagen gels which supported melanocytes and keratinocytes 
(Ng et al. 2018). Like Cubo et al a two-step process was used to first create a dermal 
construct before printing of keratinocytes and melanocytes. The fibroblast-laden 
collagen gels were printed into 6-well inserts and incubated submerged for 4 days. 
Keratinocyte and melanocyte suspensions were then printed onto the dermal construct 
Figure 1.13. H/E stained skin equivalents fabricated with microvalves. 
Representative H/E staining of a cryostat section. E represents the epidermis and D 
represents the dermis. Adapted from Ng et al 2016. 
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and incubated submerged for a further 7 days. To encourage epidermal stratification 
the constructs were cultured at an ALI for a further 4 weeks (Figure 1.13). Like the 
work of Cubo et al, the gel-based dermis had delaminated though in both cases this 
could have possibly been an artefact of the embedding or section processes. The 





Table 1.3. The printing techniques, scaffold type, cell types and the limitations 
of Studies which have bioprinted skin. 
 
The preferred approach within the literature is to use hydrogels as scaffolds to 
manufacture a cell laden dermal substrate which then can support bio-printed 
keratinocytes. This approach has been used in several, the limitation of these studies 
are summarised in table 1.3. This use of gel based bioprinting can allow the 












• Non-human ECM  
• Printed layers 
required manual 
crosslinking 
• Gel encapsulated 
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fully stratify  










• Non-human ECM 
(murine) 
• Gel encapsulated 
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• Dermal ECM was 
human (fibrin) but not 
autologous 
• Visible delamination 
of dermis 








• Source of ECM not 
specified 
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within a co-culture rather than sequential development of the two layers. By forming 
both the dermis and epidermis in parallel the lead time for equivalent production can 
be reduced, this may be an ideal approach depending on the application of the skin 
equivalent. However, there are some limitations to creating gel based HSEs. 
Encapsulating epidermal keratinocytes within a hydrogel appears to restrict 
stratification of the epidermis.  It is yet to be investigated if animal derived hydrogels 
such as non-human collagen could impact in-vitro immunotoxicity testing accuracy by 
eliciting a foreign body response. For such applications, a human fibrin-based gels 
may be more appropriate, though it may be necessary to source human leukocyte 
antigen (HLA) matched blood to prevent a background immune response and therefore 
false positives. The studies to date reflect the difficulty in bioprinting 3D skin 
equivalents and highlights that much optimisation of procedures is still required to 
develop 3D bioprinted skin equivalents with both a well-developed and physiologically 
representative dermis and epidermis. As of yet there has not been a fully autologous 
bioprinted full-thickness 3D skin equivalent available commercially or otherwise which 
is suitable for immunotoxicity testing. Therefore, there is a gap in knowledge yet to be 




1.2.6 Characterisation of Bioprinted Skin Equivalents 
Currently the gold standard within the literature for analysing the formation of skin 
equivalents is qualitative histology. Currently there are no quantitative forms of analysis 
which can verify the formation of independent dermal and epidermal layers as well as 
stratification of the epidermis. While quantitative techniques can be used to total 
expression of proteins such as cytokeratins within skin equivalents, this does not 
necessarily indicate stratified tissue, as keratinocytes are well known to terminally 
differentiate even without stratification (el-Ghalbzouri et al. 2002). For these reasons 
the literature presented in this chapter use qualitative histology as a characterisation 
tool when assessing the success of human skin equivalents (Cubo et al. 2016; Koch 
et al. 2012; Lee et al. 2014; Lee et al. 2009; Michael et al. 2013; Ng et al. 2017). One 
such example of this standard approach to characterisation is the work of Koch et al 
which presented three figures of qualitative data consisting of basic histology, 
immunohistochemistry and immunofluorescent staining (Koch et al. 2012). Therefore, 
in this thesis qualitative data was used to characterise skin equivalents developed in-
line with previous studies within the field of bioprinting skin. 
1.3 Project Aim and objectives 
This project will investigate the feasibility of bioprinting autologous human skin cells to 
produce human full-thickness 3D skin equivalents for immunotoxicity testing of 
biologics in-vitro.  
Objectives 
1. Develop robust protocols for creating handmade skin equivalents in both the 
24-well and 96-well format which are representative of physiological human 
skin. 
2. Replicate 96-well handmade skin equivalents using bioprinting and compare the 
structure to bioprinted skin equivalents to handmade skin equivalents and 
physiological human skin. 
3. Use fully autologous bioprinted skin equivalents for in-vitro testing of 





Chapter 2 Materials and Methods 
2.1 Ethical Approval 
This study was approved by the Local Research Ethics Committee (LREC). The 
primary human skin cells and blood cells used in this study were obtained from skin 
samples taken from donors after informed consent. For experiments which only 
required skin cells the cells were isolated from excess human foreskin from the urology 
clinic of the Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation 
Trust (REC 08/H0906/95+5). For experiments requiring autologous donor matched 
skin and blood cells, healthy volunteer samples were sourced by Alcyomics Ltd and 
used to isolate the required cells (REC 10/H0906/58, Appendix A). 
2.2 Skin Processing 
Skin processing and cell isolation for both cell types used a modified version of long 
established skin cell isolation protocol (Barlow and Pye 1990). Human skin biopsies 
were harvested in X-VIVO 10TM medium (Lonza) following consent from donors and 
stored at 4°C until processing. Biopsies were washed in phosphate buffered saline 
(PBS, Sigma-Aldrich) and carefully trimmed using sterile scissors and a scalpel to 
remove subcutaneous tissue. The underside of the dermis was lightly scored with a 
scalpel to facilitate enzymatic digestion of the basal membrane using dispase (Sigma-
Aldrich). The samples were then incubated overnight at 4oC in 4 mLs of a dispase 
solution to separate the epidermal and dermal layers. The dispase solution contained 
1.0 U/mL of dispase, 1% penicillin/streptomycin solution (P/S, Sigma-Aldrich) and 1% 
amphotericin B solution (Sigma-Aldrich). After dispase treatment samples were 
washed and gently agitated in PBS to remove any excess dispase and to help loosen 
the epidermis from the dermis. The epidermis was then peeled from the dermis with 






2.3 Isolation and Culture of Primary Dermal Fibroblasts 
Once separated the dermal samples were further dissected into six smaller pieces 
which varied in size. Dermal samples were placed into 6-well plates (Greiner 
CELLSTAR®, Sigma-Aldrich). The bottom of each well was scored with a scalpel to 
improve adhesion of the sample to the well. Any excess PBS from each dermal sample 
was aspirated and 100 µL of foetal bovine serum (FBS, Thermo Fisher Scientific) was 
used to cover each dermal sample. The dermal samples were incubated at 37oC with 
5% CO2 for 24 hours. The following day the wells were topped up with 5 mLs of 
complete Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich) supplemented 
with 20% FBS, 1% penicillin/streptomycin solution (P/S, Sigma-Aldrich), 1% l-
glutamine solution (Sigma-Aldrich) and 1% amphotericin B solution (Sigma-Aldrich) 
was added. After 3 days the media was replaced with complete DMEM with 10% FBS. 
Beyond this stage DMEM supplemented with 10% FBS, 1% P/S and 1% amphotericin 
B was used as fibroblast growth medium. The dermal samples were fed twice weekly 
with 5 mLs of fibroblast growth medium until sufficient fibroblast outgrowth from the 
dermis was observed. This was considered as passage 0. Once enough outgrowth 
was observed the dermis was then removed with ethanol sterilised forceps and 
discarded. The fibroblast growth medium was aspirated, and wells were washed twice 
Figure 2.1. Enzymatically separated dermis and epidermis of a 4mm skin punch 
biopsy. The floating epidermis is indicated by the red arrow, while the thicker dermis 




with PBS. The fibroblasts were enzymatically dissociated by incubation with trypsin-
EDTA (Sigma-Aldrich) for 5 minutes at 37oC with 5% CO2. Once the fibroblasts were 
detached fibroblast growth medium equal to the volume of trypsin-EDTA was added to 
each well and the cell suspension was aspirated and pelleted by centrifuging 
(Megafuge 8, Thermo Fisher) at 400g for 5 minutes. Cells were resuspended in 
fibroblast growth medium and counted using a haemocytometer (Hawksley). 
Fibroblasts were further cultured in tissue culture flasks (Greiner, Sigma-Aldrich) with 
the media changed twice weekly. Cells which were not intended for immediate use in 
experiments were stored at -140oC at passage 2 for future use. Fibroblasts used for 
experiments were not cultured beyond passage 7. To cryopreserve the fibroblasts the 
cells were dissociated from flasks using trypsin-EDTA and pelleted by centrifugation at 
400g for 5 minutes. The supernatant was discarded, and the cells were resuspended 
at 1 x 106 cell/mL with fibroblast freezing solution consisting of 9 parts fibroblast growth 
media and 1 part dimethyl sulfoxide (DMSO, Fisher Scientific). The DMSO prevented 
the formation of ice crystals when freezing which could cause cell death. The cells 
were transferred to cryovials (Nunc, Sigma-Aldridge) and frozen at -80oC overnight to 
achieve a freezing rate of -1oC/min. The following day cryovials were transferred to a -
140oC freezer for long term storage. 
2.4 Isolation and Culture of Primary Keratinocytes 
Following the separation of the dermis from the epidermis, the epidermis was not 
further dissected into smaller pieces. Rather the epidermis was incubated with trypsin-
EDTA at 37oC with 5% CO2 for 5 minutes. After 5 minutes an equal volume of fibroblast 
growth media was added to the epidermis to neutralise the trypsin-EDTA. The 
suspension containing the epidermis was centrifuged for 5 minutes at 400g. After 
centrifugation, the trypsin-EDTA/fibroblast growth media solution was decanted and 
the epidermis along with the cell pellet, was resuspended in keratinocyte growth media 
and seeded into a tissue culture flask. This was considered passage 0. The 
keratinocyte growth media was EpiLife® Medium (Thermo Fisher Scientific) 
supplemented with 1% human keratinocyte growth supplement (HKGS, Thermo Fisher 
Scientific), 1% P/S, and 1% amphotericin B solution. The following day the floating 
epidermis was removed, and the media changed to remove any non-adherent cells. 
The remaining adherent keratinocytes within the flask where fed thrice weekly and split 
using trypsin-EDTA once reaching 70% confluency. Keratinocytes were not cultured 
beyond passage 4. Keratinocytes which were not intended for immediate use were 
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cryopreserved at passage 1 or 2 using the process described for freezing of fibroblasts, 
but with the keratinocytes frozen in a keratinocyte freezing solution consisting of 9 parts 
keratinocyte growth media and 1 part DMSO. 
2.5 Peripheral Blood Monocytes Isolation from Whole Blood 
Cell isolation from whole blood was conducted using a modified method described by 
(Yeo et al. 2009). For experiments which required donor matched autologous 
peripheral blood monocytes (PBMCs) 60 mL of whole blood from healthy human 
volunteers was provided by Alcyomics Ltd. Whole blood was provided in sodium 
heparin blood tubes (BD, Fisher Scientific) to prevent coagulation of blood, additionally 
approximately 8 mL of whole blood was provided in a serum tube (BD, Fisher Scientific) 
which contained clot activators. The serum tube was centrifuged at 400g for 5 minutes 
to separate serum from blood cells. After centrifugation, 1 mL of serum was aspirated 
from the serum tube without disturbing the blood clot and aliquoted into an Eppendorf 
tube. The serum was heat inactivated at 56oC for 1 hour then stored at -80oC for future 
use. The blood from the sodium heparin tubes was diluted 1:1 with Earle’s Balanced 
Salt Solution (Sigma-Aldrich) and carefully layered onto 6 mL of Lymphoprep™ density 
gradient medium (STEMCELL Technologies) so as not to mix the diluted blood and 
the Lymphoprep™ (Figure 2.2). The tubes containing layered blood and lymphoprep 
were centrifuged at 800g for 15mins (FisherScientific Accuspin). During centrifugation, 
the granulocytes, and erythrocytes sedimented through the Lymphoprep™ solution 
due to a higher density at the osmotic pressure of the density gradient medium. The 
less dense monocytes remained at the plasma-Lymphoprep™ interface (Figure 2.2). 
The plasma directly above the PBMC layer was discarded and the PBMC layer at the 
plasma- Lymphoprep™ interface was harvested. PBMCs were washed in PBS, 
centrifuged, and resuspended in RF10 media and counted. RF10 was comprised of 
Roswell Park Memorial Institute-1640 (RPMI-1640, Sigma-Aldrich) media 
supplemented with 10% FBS, 1% P/S, 1% amphotericin B solution, and 1% l-glutamine 
solution. The PBMCs were frozen in a freezing solution containing 9 parts RF10 and 1 
part DMSO. PBMCs were stored at -140oC for further experiments. 
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2.6 Producing Handmade Skin Equivalents Using Transwell Inserts  
To develop consistent three-dimensional (3D) models, smaller prototypes of Alvetex® 
transwell inserts initially used in 6-well format by used by Hill et al (Hill et al. 2015) were 
used. The smaller prototypes were used in the 24-well format and the 96-well format 
inserts and were provided by Reprocell Europe Ltd (Figure2.3). The transwell system 
was used to ensure that the resulting human skin equivalents (HSEs) would be fully 
human and not contain animal extra-cellular matrix (ECM). The general protocol for 
constructing handmade and bioprinted HSEs between 24-well and 96-well formats was 
largely unchanged from the original 6-well format first described by Hill et al (Hill et al. 
2015). This process is summarised in Figure 2.4.  
 Figure 2.3. Alvetex® transwell inserts. 1) 6 well insert used by Hill et al (Hill et al 
2015)). 2) Prototype 24-well transwell inserts. 3) Prototype 96-well transwell inserts. 
Figure 2.2. Density gradient separation of monocytes from whole blood. Diluted 
whole blood was layered onto lymphoprep and centrifuged to separate cells by density 






Before use, the prototype transwell Alvetex® inserts were soaked in 70% ethanol for 
60 seconds. The ethanol both sterilised the scaffold and rendered the material 
hydrophilic, allowing media and cells to penetrate the scaffolds.  Excess ethanol was 
fully removed by washing the inserts in several changes of PBS followed by washes in 
three changes of fibroblast growth media. The primed inserts were transferred to a new 
sterile tissue culture plate (Greiner CELLSTAR®, Sigma-Aldrich), and excess 
fibroblast growth media was carefully aspirated from the outer well and from within the 
transwell insert without damaging the scaffold. To form a dermal equivalent, primary 
dermal fibroblasts were seeded onto the top of the scaffold first. The primary fibroblasts 
were used up to passage 7. Prior to seeding fibroblasts, fibroblast growth media was 
added to the outside of each well to ensure that the bottom of the scaffold was in 
contact with media. The cell suspension containing the dermal fibroblasts was carefully 
pipetted directly onto the centre of the scaffold. The plates containing the dermal 
fibroblasts were carefully transferred to an incubator and incubated for 90 minutes at 
37°C with 5% CO2. After this time, fibroblast growth media was carefully pipetted to 
the outside of each well, gently flooding the chamber of the transwell inserts and 
submerging the scaffold containing the fibroblasts. Dermal equivalents were fed daily 
with fibroblast growth media supplemented with 100µg/mL of ascorbic acid (Sigma-
Figure 2.4. Diagram of 3D skin equivalent culture method. (A) Dermal 
incubation of fibroblasts only for up to 28 days. (B) Basal incubation of 
keratinocytes for 3 days. (C) Incubation of model at air-liquid interface for 14 days. 
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Aldrich). Fibroblasts were left to grown in the scaffold and produce extracellular matrix 
(ECM) and develop a dermal equivalent for at least 18 days. The production of dermal 
ECM by the fibroblasts was needed to prevent any infiltration of keratinocytes into the 
scaffold and to allow the formation of an epidermal layer. To form the epidermal layer, 
the dermal equivalents which had already been growing for at least 18 days were first 
prepared for seeding with keratinocytes. The fibroblast growth media was aspirated, 
and the dermal equivalents were rinsed with PBS to remove any residual fibroblast 
growth media present within the outer well. Once the PBS was aspirated from the outer 
well basal media was pipetted to the outside of each insert to ensure that the bottom 
of the dermal equivalent was in contact with media. The basal media consisted of a 
3:1 ratio of DMEM and Ham’s F12 nutrient mixture (Sigma-Aldrich) supplemented with 
5% chelex-treated FBS, 1% P/S, 1% amphotericin B, 8.5 ng/mL of cholera toxin 
(Sigma-Aldrich) 0.4 μg/mL hydrocortisone (Sigma-Aldrich), 5 μg/mL of human insulin 
(Sigma-Aldrich), 24 μg/mL of adenine (Sigma-Aldrich), and 20 ng/mL of human 
epidermal growth factor (hEGF, Peprotech). Chelex-treated FBS was prepared by 
adding 100g of Chelex-100 resin (BioRad) to 500 mL of FBS and stirring overnight at 
4oC. The resin slurry was then removed by filtering the treated FBS with Whatman filter 
paper (Thermo Fisher Scientific). Before use, the Chelex-treated FBS was sterile 
filtered using a 0.2µm syringe filter (Thermo Fisher Scientific). Keratinocytes were used 
up to passage 4 and were resuspended in basal media. The keratinocyte suspension 
was seeded onto each respective dermal equivalent and then incubated for 3 hours at 
37 °C with 5% CO2. After the 3 hour incubation basal media was slowly added to the 
outside of each well to gently submerge the keratinocytes with minimal disturbance. 
The keratinocytes were cultured sumberged for 3 days to allow the cells to proliferate 
and form a basal monolayer on the dermis. The basal media was changed daily. 
To encourage the formation of a stratified epidermis, the skin equivalents were raised 
to the air-liquid interface (ALI) after 3 days of submersion in basal media. To raise the 
model to ALI, the basal media was aspirated from each well and replaced with ALI 
media added to the outside of the insert ensuring the media was in contact with the 
underside of the dermal equivalent. The ALI media consisted of a 3:1 ratio of DMEM 
and Ham’s F12 nutrient mixture supplemented with 10% FBS, 1% P/S, 1% 
amphotericin B, 8.5 ng/mL of cholera toxin, 0.4 μg/mL hydrocortisone, 20 ng/mL of 
EGF, 5 μg/mL human transferrin (PeproTech) and 100 μg/mL ascorbic acid. Enough 
ALI media was added to each well making sure the bottom of the equivalent was in 
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contact with ALI media while the keratinocytes were exposed to air. Skin equivalents 
were cultured for 14 days at the ALI, media was changed every 24 hours. After 14 days 
of incubation at ALI the media was aspirated, and the equivalents were carefully 
washed with PBS to remove any excess media and then harvested. 
2.6.1 Optimisation of Handmade 24-well Skin Equivalents 
Initially a protocol developed by Alcyomics was used to construct 24-well based HSEs 
by adapting the work of Hill et al (Hill et al. 2015), this protocol was later optimised. 
The prototype 24-well inserts were manufactured with the aim of reducing the overall 
number of cells necessary to create 3D skin equivalents from the original work (Hill et 
al. 2015). The rationale for decreasing the number of cells per HSE was to potentially 
increase the number of skin equivalents that could be constructed per donor.  
In the 24-well format fibroblasts were suspended at a concentration of 20 x 106 
cells/mL. 50 µL of this cell suspension was seeded onto each scaffold. 1 mL of 
fibroblast growth media was added to the outside of each well to ensure that the bottom 
of each scaffold was in contact with media. After the 90-minute incubation a further 
600μl of fibroblast growth media was carefully pipetted to the outside of each well. For 
the epidermal layer, keratinocytes resuspended in basal media at  20 x 106 cells/mL. 
50 µL of the keratinocyte suspension containing 1 x 106 keratinocytes were seeded 
onto each dermal equivalent. To raise the HSEs to the ALI in the 24-well format the 
basal media was aspirated and 1 mL of ALI media was added to the outer well. Once 
mature 24-well HSEs were washed in PBS. The HSEs were carefully unclipped from 
the transwell inserts, cut in half using a scalpel (Thermo Fisher), covered in tissue wrap 
(Fisher scientific) and placed into tissue cassettes (Fisher scientific). The tissue 
cassettes were submerged in 10% neutral buffered formalin for at least 24 hours. The 
formalin fixed samples were processed, paraffin embedded, sectioned, and stained 
with haematoxylin and eosin (H&E) by the Department of Cellular Pathology, Royal 
Victoria Infirmary, Newcastle upon Tyne.  Further analysis of the structure of the 24-
well skin equivalents were observed through histological staining techniques as 
described in section 2.11. 
2.6.2 Development of Handmade 96-well based model 
As there was no established protocol for the fabrication of handmade 96-well skin 
equivalents using the 96-well prototype Alvetex® inserts (provided by Reprocell 
Europe Ltd), it was necessary to investigate the number of fibroblasts and dermal 
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incubation period required for the development of the dermal layer prior to optimising 
the formation of an epidermal layer. The fabrication protocol was optimised by hand 
prior to being replicated with bioprinting. The processing, embedding, and sectioning 
of models made with 96-well Alvetex® inserts are detailed in section 2.11. 
2.6.2.1 96-well Dermal Equivalent Optimisation 
To form a dermis there needs to be enough fibroblasts to both adequately populate the 
scaffold and produce enough ECM to support an epidermis and prevent infiltration of 
keratinocytes into the scaffold. Varying numbers of fibroblasts (1 x 105, 3 x 105, 5 x 105 
and 7 x 105) were suspended in fibroblast growth media and seeded onto 96-well 
scaffolds. These numbers were chosen as the 96-well scaffold was approximately one 
quarter the size of the 24-well scaffold. Cells were seeded in a final volume of 20 µL of 
per scaffold. To prevent the underside of the dermis from drying 150 µL of fibroblast 
growth media was added to the outside of the wells. After the 90-minute incubation 50 
µL of fibroblast growth media was added to each well to fully submerge the scaffolds. 
The dermal equivalents were fed daily with fibroblast growth media supplemented with 
100 µg/mL ascorbic acid and harvested after 10, 14 and 18 days of culture. Harvested 
equivalents were washed in PBS and submerged in 10% neutral buffered formalin for 
24 hours. Dermal equivalents were processed, embedded, sectioned and structurally 
validated by haematoxylin and eosin (H&E) staining and Picro-Sirius red staining as 
described in section 2.11.3. 
2.6.2.2 96-well Full-thickness Equivalent Optimisation 
Different numbers of keratinocytes (1 x 105, 3 x 105, 5 x 105 and 7 x 105 cells) were 
seeded onto 96-well dermal equivalents to investigate how many cells were required 
to form an epidermis. Dermal equivalents were made with both 3 x 105 and 5 x 105 
fibroblasts and incubated for 18 days. Keratinocytes resuspended in 20 µL of basal 
media were seeded onto the surface of each dermal equivalent. 150 µL of basal media 
was added to the outer well. After the 3 hours incubation an additional 50 µL of basal 
media was added to the outside of each well, fully submerging the equivalents. To 
raise HSEs to ALI culture the basal media was aspirated and adding 150 µL of ALI 
media added to the outer well. Equivalents were cultured at ALI for 14 days with media 
changed twice daily. On day 14 equivalents were harvested, washed once in PBS, and 
fixed in 10% neutral buffered formalin for 24 hours.  
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2.7 Bioprinting of Skin Cells to Fabricate Skin Equivalents 
Before bioprinting skin equivalents variables such as the jetting parameters, the 
number of cells in suspension, and the deposition volume, required thorough 
optimisation to ensure that prepared scripts were robust and reproducible for model 
development. The methods described in following bioprinting subsections were 
developed and optimised within this thesis. 
2.7.1 Bioprinter Apparatus 
For this study, a Microfab Jetlab 4 XL (Microfab Technologies Inc.) printer, shown in 
Figure 2.5, was retrofitted to accommodate solenoid micro dispensing valves 
(INKX0514300AA, Lee Products Ltd) to create a high throughput bioprinting platform. 
The inkjet printhead of the Jetlab 4 printer was replaced with a microvalve printhead 
(Figure 2.6) that could accommodate four individual custom-built ink reservoirs each 
with an ink capacity of 2.5 mL. The outlets of the reservoirs were threaded to contain 
a male-male 062 MINSTAC threaded connector (Lee Products Ltd) one side of which 
was fixed into the reservoir (Figure 2.7). The other end of the male-male connector 
was used to attach the solenoid VHS series micro dispensing valve (Figure 2.7). The 
valve configuration used in this study had female 062 MINSTAC threaded inlets and 
outlets allowing the design of a modular printhead which could be used with various 
062 MINSTAC threaded valves and nozzle types. 062 MINSTAC jewelled orifice 
nozzles (Lee Products Ltd) with orifice diameters of 190.5μm were used with the VHS 
series valves as they could be removed and sonicated to remove biological debris 
without causing any damage to the nozzle. To convert device waveforms to be 
compatible with the solenoid valves it was necessary for spike and hold electrical 
drivers (Lee Products Ltd) to be connected to both the Jetlab 4 device signal output 
channels and the signal connections of the individual valves. This allowed signals 
produced by the waveform printed circuit board (PCB) of the Jetlab to be converted to 
a 24V spike voltage to open a valve as quickly as possible and a 5V dwell voltage to 













Figure 2.6. Modified Jetlab 4 Tabletop. (1). PC used to run Jetlab software. (2) DC 
power supply unit. (3) Potentiometer controlling agitation speed. (4) Z axis print head. 
(5) XY printing platform. (6) Pneumatic pressure controllers. (7) Emergency stop. (8) 
On/off switch. 
Figure 2.5. Unmodified Jetlab 4 XL. Image from www.microfab.com. 
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To operate the bioprinter, jetting parameters and xyz coordinates were defined by user 
input via Jetlab software provided with the Jetlab 4 system. The two key variables 
which influenced volume dispensed per drop were dwell time (duration of dwell voltage, 
see Figure 1.7) and pneumatic back pressure. Dwell time was adjusted via the Jetlab 
software while the backpressure was manually adjusted by the pressure controllers 
located on the front of the Jetlab (Figure 2.5). To reduce cell sedimentation within the 
reservoir, an agitation system (designed by Dr Matthew Benning, Newcastle 
University) was used to agitate the cells within the reservior. A gold-plated magnet 
(First4magnets) was added directly into the reservoir with the bio-ink to agitate the 
cells. The magnet in the reservoir was rotated by rotating a metal shaft located 
perpendicular to the reservoir. The shaft was connected by a drive belt to a DC 24V 
motor (RS Components). The voltage supplied to the motor determined the agitation 
speed of the magnet within the reservoir. For printing of cells this motor was operated 
at 18 volts. 
  
Figure 2.7. Components within the bioprinter cabinet. (1) Ink reservoir. (2) 
Solenoid valve. (3) Removable nozzle. (3) Metal agitation rod. (4) 24V motor. (5) 
Backpressure tubing. (6) Valve actuation signal wiring. (7) XY printing platform. (8) 
Drop analysis camera. (9) Stroboscopic LED. 
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2.7.2 Investigating the Influence of Dwell Time and Back Pressure on Droplet 
Volume 
To select the printing parameters to bioprint human skin cells a study was conducted 
to investigate the range of volumes per droplet that could be dispensed by the 
bioprinter. This study involved investigating the relationship between valve dwell time 
and pneumatic back pressure on the volume of bio-ink dispensed. To quantify the 
volume dispensed, 200 droplets of fibroblasts growth media was dispensed into a 1.5 
mL Eppendorf tube. The Eppendorf tubes were weighed with a microbalance before 
and after printing. Dwell times of 100-1000µs were investigated with measurements 
taken at increments of 50µs. These experimental limits were chosen as dwell times of 
less than 100µs did not produce droplets whereas dwell times larger than 1000µs 
resulted in the formation of droplet ligaments and satellite droplets which could affect 
printing accuracy. Backpressures of 50-500mmHg were investigated with 
measurements taken at increments of 50mmHg. Backpressures of less than 50mmHg 
did not consistently generate droplets and so were not investigated. The backpressure 
was limited to 500mmHg as backpressures greater than 500mmHg caused splashing 
on printing substrate which adversely affected printing accuracy. The volume per 
droplet (d) was calculated using Equation 1. Prints were conducted in triplicate to 





Equation 1. Calculation for volume per droplet (µL). d denotes the volume per 
droplet. W1 and W2 represent weight of collection tube in grams before and after 
printing, respectively. The number of droplets printed is represented by n. 
 
2.7.3 Bioprinting of Skin Cells 
To investigate the relationship between the number of cells within the bio-ink and the 
number of cells dispensed, a range of cell numbers were loaded into reservoirs and 
printed into a 24-well plate over 1 hour. The cells printed in this experiment were 
primary dermal fibroblasts which were suspended into fibroblast growth media at 1 x 
106 cells/mL, 10 x 106 cells/mL, 20 x 106 cells/mL, and 40 x 106 cells/mL. This 
experiment was carried out using biological triplicates to account for donor to donor 
variation in cell viability. Cells were loaded into the printer and 100 µL of the ink 
containing the cell suspension was printed at 0 minutes, 15 minutes, 30 minutes, 45 
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minutes, and 60 minutes. To print 100 µL of ink directly into a 24-well plate a circular 
monochromatic bitmap (BMP) scaled to a 24-well plate was created to dispense cells 
directly into the centre of each well (Figure 2.7). Each pixel was recognised by the 
software as a droplet and BMPs were printed into each well with user defined 
parameters. The BMPs were printed with a back pressure of 150mmHg, a droplet 
spacing of 0.15mm, a dwell time of 900μs and a fly rate of 35mm/s. 150mmHg was 
selected to reduce potential shear stress to cells during the printing process. The 
900µs dwell time allowed a large volume per droplet while limiting the formation of 
satellite droplets. The fly rate was this speed at which the printhead moved across the 
x-axis. As the volume per droplet (d) at these parameters was previously calculated it 
was possible to calculate the total number of pixels/droplets in a bitmap (P) required 
to print a total volume (Vt) of 100 µL. The number of pixels required per BMP (P) was 
calculated using Equation 2. Prior to printing cells, the total volume dispensed (Vt) 
when printing BMPs was confirm by weighing media printed directly onto glass slides. 
Slides were weighed using a microbalance. Once printed the number of cells were 
manually counted and cell viability was recorded using a trypan blue exclusion assay 






Equation 2. Calculation for the number of pixels required per bitmap. P represents 
to number of pixels within a bitmap. Vt represents the total volume to be dispensed. 
The volume per droplet is represented by d. 
A B 
Figure 2.8.Well shaped monochromatic bitmap (bmp). A) An example of a well-
shaped bmp which is recognised by the Jetlab software as a printing pattern. B) A well-
shaped bmp printed onto a glass slide and imaged with a Leica M205 C Stereo 




2.7.4 Bioprinting of Full-Thickness 96-well based Skin Equivalents  
To bioprint cells directly onto the prototype 96-well Alvetex® scaffold, printing scripts 
were adjusted to deposit a Vt of 20 µL per well. Due to the unique shape of the transwell 
insert a small but simple square array was scripted to replace the bitmaps used 
previously. The backpressure was 150mmHg and the dwell time was 900µs used. A 
backpressure of 150mmHg was used to minimise potential shear stress on cells during 
the printing process. The dwell time of 900µs was selected increase the volume per 
droplet without forming large droplet ligaments and satellite droplets. The number of 
droplets required within both x and y axis of the scripted array (D) were calculated 
using Equation 3. To ensure the printed array would fit into the transwell cradle, the 
spacing between droplets was reduced to 0.02mm. To confirm that 20 µL would be 
dispensed per well, media was dispensed onto glass slides using the above 
parameters and the weight of the dispensed media was measured using a 
microbalance. This was done in triplicate to account for variability in measurements. 
Before printing full-thickness skin equivalents the number of printed cells per well was 
confirmed by manually counting the dispensed cells, and cell viability was assessed 
by trypan blue exclusion assay (section 2.8). This was carried out using both primary 
dermal fibroblasts and keratinocytes in biological triplicates to account for donor to 
donor variation in cell viability. Dermal equivalents were bioprinted first by suspending 
fibroblasts at 25 x 106 cells/mL in fibroblast growth media and dispensing the cells onto 
scaffolds using the optimised parameters. Dermal equivalents were cultured for 18 
days as detailed in section 2.6.2.  After day 18 the dermal equivalents were washed 
with PBS in preparation for bioprinting of keratinocytes. Keratinocytes were suspended 
in basal media at 20 x 106 cells/mL and printed onto dermal equivalents. Equivalents 





Equation 3. Calculation for the number of droplets required in the X and Y axis 
of an array of droplet. D represents the number of droplets in X and Y axis of array. 





2.8 Trypan Blue Exclusion Assay 
To distinguish between viable and non-viable cells in cell suspensions post printing 
trypan blue (Sigma-Aldrich) was used. This methodology was a modified protocol 
described by W Strober (Strober 2015). Trypan blue is negatively charged and so 
interacts with cells that have compromised membranes. Therefore, viable cells were 
not stained while cells with damaged membranes (non-viable cells) were stained blue. 
30 µL of a cell suspension was mixed 1:1 with 30 µL of 0.2% trypan blue. The mixture 
was loaded into a Neubauer haemocytometer and both live and dead cells were 
counted using an upright Zeiss Jenamed 2 microscope (Carl Zeiss Ltd).  The 
percentage of viable cells was calculated using Equation 4. 
% 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠 = (𝑙𝑖𝑣𝑒 𝑐𝑜𝑢𝑛𝑡 ÷ 𝑡𝑜𝑡𝑎𝑙 𝑐𝑜𝑢𝑛𝑡) × 100 
Equation 4. Equation used to calculate cell viability of trypan blue exclusion 
assay. 
2.9 In-vitro Testing of Biologics with Bioprinted Skin Equivalents 
In-vitro testing of biologics using skin equivalents was carried out with fully autologous 
skin equivalents in biological triplicates. Autologous skin equivalents were bioprinted 
as outlined in section 2.7.4. The matured skin equivalents were washed twice with PBS 
before co-culture with autologous PBMCs. Autologous media was used for the skin 
equivalent-PBMC co-culture which consisted of RPMI, 10% heat-inactivated 
autologous serum, 1% P/S solution and 1% l-glutamine solution. The autologous skin 
equivalents were co-cultured in 96- well plates with 1 x 106 PBMCs per well. Two 
biologics were tested alongside two negative controls. The first biologic, Natalizumab 
(pharmaceutical name Tysabri) is used in clinic to treat relapsing multiple sclerosis and 
has been shown to cause little immunotoxicity in human settings (Fletcher et al. 2018). 
The second biologic was a murine anti-human CD3 antibody, also known as OKT3 
(marketed under muromonab), which was the first monoclonal antibody (mAb) to be 
approved for use in humans (Kuhn and Weiner 2016). Both mAbs were provided by 
Alcyomics Ltd and were tested at a final concentration of 1 µg/mL. The negative 
controls were autologous skin equivalents incubated with autologous media only 
(media control) and autologous skin equivalents incubated with PBMCs without mAbs 
(PBMC control). The co-cultures were incubated at 37oC with 5% CO2 for 3 days. After 
3 days 100 µL of supernatant was aspirated to analyse proinflammatory cytokine 
release from each co-culture and stored at -20oC until used. 
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2.10 Embedding and Sectioning of 96-well Skin equivalents 
Due to the small size and unique design of the prototype inserts, the Alvetex® scaffold 
could not be easily removed from the transwell insert without heavily damaging the full- 
thickness skin equivalents. Therefore, rather than removing the scaffold which was 
heat welded to the insert, the insert was trimmed after processing and paraffin 
embedded with the Alvetex® still attached.  
2.10.1 Manual Processing and Embedding of Skin Equivalents 
Following fixation, skin equivalents were manually dehydrated to remove water present 
within the equivalent. This was necessary as the hydrophobic paraffin wax would not 
be able to permeate the tissue in the presence of water. To dehydrate the skin 
equivalents the tissues were immersed in a series of ethanol solutions increasing in 
concentration with a final immersion in 100% ethanol at room temperature (table 2.1). 
The increasing concentration of ethanol allowed the water present in the skin 
equivalents to gradually be replaced with ethanol. Histoclear II (National Diagnostics) 
was used to remove ethanol from the skin equivalents at room temperature followed 
by immersion in a solution containing an even mixture of histoclear II and molten 
paraffin wax (Thermo Fisher Scientific) at 60oC. Skin equivalents were then incubated 
in 100% molten paraffin wax, allowing the wax to fully penetrate the skin equivalent. 
Once fully immersed in wax samples were embedded into paraffin blocks using a 





Table 2.1. 96-well skin equivalent processing procedure. Skin equivalents were 
dehydrated with ethanol to gradually remove water. Ethanol was replaced with 




Reagent Incubation time (minutes) Incubation temperature (
o
C) 
30% ethanol 10 18-26 
50% ethanol 10 18-26 
70% ethanol 10 18-26 
80% ethanol 10 18-26 
90% ethanol 10 18-26 
95% ethanol 10 18-26 
100% ethanol 20 18-26 
100% Histoclear II 30 18-26 
50:50 histoclear II: paraffin mixture 30 60 
100% paraffin 30 60 
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2.10.2 Sectioning of Skin Equivalents 
To section paraffin blocks, a HM 325 microtome (Thermo Fisher Scientific) with XM35 
microtome blades (Thermo Scientific) was used to cut 4µm thick sections. Embedded 
biopsies and 24-well equivalents were cooled for several minutes using the cold plate 
of the embedding station before sectioning on the microtome. Sections were 
transferred to a paraffin section flotation bath (Cole-Parmer), mounted onto superfrost 
slides (Thermo Fisher Scientific) and baked in an oven overnight (dry-line, VWR). 
Blocks containing 96-well skin equivalents were cooled in a fridge for 10 minutes before 
sectioning (Figure 2.8).  96-well skin equivalent blocks required trimming to cut through 
the plastic cradle and section the skin equivalent. 
Figure 2.9. Embedding orientation and sectioning of 96-well skin equivalents. A) 
Orientation of skin equivalents embedded in paraffin blocks. B) An embedded 96-well 
skin equivalent which was trimmed to cut through the cradle and reveal the skin 
equivalent. C) Floating section of a 96-well block cooled on a histostar cooling plate. The 
damaged skin equivalent is indicated by the black arrow. D) Section of a 96-well skin 
equivalent that was cooled in a fridge before cutting. Intact skin equivalent is indicated 





























2.11 Histological Techniques 
To image skin equivalents a range of histological techniques were used to highlight the 
general structure of tissue or specific markers located within the dermis or epidermis. 
2.11.1 Haematoxylin and Eosin Staining 
Haematoxylin and eosin (H&E, Thermo Fisher Scientific) were used to stain the 
general structure of physiological human skin and skin equivalents using a protocol 
developed and optimised by Alcyomics. Haematoxylin stains the basophilic structures 
(nuclei) blue/purple while eosin stains acidophilic structures (cytoplasm) pink. 4µm 
sections were deparaffinised through two washes in xylene (Fisher Scientific) followed 
by rehydration through a decreasing gradient of alcohols (100%, 70% and 30% 
ethanol) ending with rehydration in tap water. Rehydrated sections were immersed with 
haematoxylin for 5 minutes then rinsed in tap water to remove excess dye. Slides were 
then placed in Scott’s tap water for 30 seconds before being rinsed under running tap 
water. Scott’s tap water was used as a blueing agent to improve the contrast between 
haematoxylin and eosin. Sections were then stained with eosin for 2 minutes and again 
rinsed in tap water. Stained sections were dehydrated through graded alcohols (30%, 
70%, and 100% ethanol) cleared in two changes of xylene and mounted using DPX 
mountant (Sigma-Aldrich). Images were captured using an Axioimager microscope 
(Carl Zeiss Ltd). 
 
2.11.2 Immunofluorescent Staining 
Immunofluorescent (IF) staining was used to stain for specific dermal and epidermal 
components. A modified version of the IF procedure described by Hill et al was used 
(Hill et al. 2015). To optimise the IF staining procedure primary antibodies specific for 
human epitopes were titrated using the procedures described in this section. All 
primary antibodies were purchased from Abcam. Sections of human skin provided by 
healthy donors were used as positive controls to optimise the IF protocol and antibody 
concentrations. For staining of dermal components mouse anti-collagen III was titrated 
to detect dermal ECM. To detect the presence of the basement membrane mouse anti-
collagen IV, mouse anti-collagen VII and rabbit anti-laminin-5 were also titrated. The 
optimised protocols were then used to validate the structure of the 3D skin equivalents 
by locating epidermal markers. The primary antibodies used for staining of epidermal 
markers were mouse anti-cytokeratin 14 1:250, rabbit anti-involucrin 1:400, rabbit anti-
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cytokeratin 10 1:500, and rabbit anti-loricrin 1:125 all of which were purchased from 
Abcam. The secondary antibodies were goat anti-mouse Alexa Fluor-488 (AF-488) 
(Thermo Fisher Scientific) and goat anti-rabbit Alexa Fluor-647 (AF-647) (Thermo 
Fisher Scientific), both used at 1:200. Sections were baked and taken to water and 
then submerged in pH 6.0 citrate buffer for heat mediated antigen retrieval for up to 10 
minutes. Antigen retrieval was necessary as methylene bridges which form during 
fixation with formalin, could have potentially masked target epitopes, preventing the 
primary antibody from binding to the target. After this step, the sections were washed 
with 5mM tris buffered saline (TBS) pH 7.6 for 5 minutes. 0.2% Triton-X was then used 
to permeabilise sections for 10 minutes at room temperature followed by a TBS wash. 
The sections were then blocked with 10% goat serum (Sigma-Aldrich) for up to one 
hour at room temperature to limit non-specific binding of the primary antibodies. The 
residual goat serum was removed by washing twice with TBS. The primary antibodies 
were applied to the sections for 1 hour at room temperature. For each primary antibody 
used a null primary slide was also prepared. The null primary slides were used as 
negative controls and were incubated with blocking solution rather than a primary 
antibody. The null primary slides were used to establish microscope parameters before 
imaging other sections. After 1-hour primary antibodies were removed and slides were 
washed in TBS. The fluorophore conjugated secondary antibodies were then applied 
to all slides including the null primaries for 2 hours at room temperature protected from 
light. Slides were washed again in TBS to remove the secondary antibody. Cell nuclei 
were counterstained with 5 μg/mL of Hoechst 33342 (Sigma-Aldrich) for 10 minutes 
protected from light at room temperature. Sections were again washed with TBS before 
dehydration through graded alcohols and were washed twice in xylene. Coverslips 
were mounted with DPX mountant. Fluorescent images were captured using an 
Axioimager microscope (Carl Zeiss Ltd) with Hoechst 33342, Alexa Fluor 488, and 
Alexa Fluor 647 filters. 
 
2.11.3 Picro-Sirius Red Staining 
A Picro-Sirius Red kit (Abcam) was used to detect the development of dermal ECM 
(collagen I and III) generated by dermal fibroblasts in the skin equivalents. Picro-Sirius 
Red stains collagen type I and type III red while staining cell cytoplasm and nuclei 
yellow. Staining was conducted as per manufacturer instructions. 4μm sections were 
washed twice in xylene and rehydrated through graded alcohols. Rehydrated sections 
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were covered with neat Picro-Sirius Red solution and incubated in a humidified 
chamber at room temperature for 1 hour. The sections were then rinsed twice in two 
quick changes of acetic acid (Abcam) and rinsed once in absolute ethanol (Sigma-
Aldrich). Sections were then dehydrated through graded alcohols and mounted in DPX 
mountant (Sigma-Aldrich). The speed of the dehydration in 100% ethanol influenced 
the strength of the yellow cytoplasm and nuclei staining. Slides dehydrated quickly 
resulted in clear contrast between collagen and cell nuclei/cytoplasm, whereas slides 
that were overexposed to 100% alcohol had orange nuclei/cytoplasm. Images were 
captured using an Axioimager microscope (Carl Zeiss Ltd) with unpolarised light. 
2.11.4 Periodic Acid-Schiff Staining 
Periodic Acid-Schiff (PAS) stains tissues rich in polysaccharides such as glycogen 
(Tabatabaei Shafiei et al. 2014). PAS (Sigma-Aldrich) was used to detect 
mucopolysaccharides, specifically glycoproteins present within the basement 
membrane, which is located at the dermal-epidermal junction in healthy human skin. 
Staining was conducted as per manufacturer instructions. Deparaffinised sections 
were rehydrated and immersed in periodic acid solution for 5 minutes. Periodic acid 
solution oxidises glycols in tissue to aldehydes.  Excess periodic acidic solution was 
removed by rinsing slides in several changes of distilled water. Slides were then 
immersed in Schiff’s reagent for 15 minutes. Schiff’s reagent reacts with aldehydes to 
form a magenta stain. Slides were washed under running water for 5 minutes followed 
by counter staining of nuclei with haematoxylin. Excess haematoxylin was removed by 
rinsing slides in tap water and then slides were dehydrated and mounted in DPX 
mounting resin. Images were captured using an Axioimager microscope (Carl Zeiss 
Ltd). 
2.12 Multiplex Proinflammatory Cytokine Detection Assay 
To quantify cytokine secretion in supernatants of autologous skin equivalent-PBMC 
co-cultures, a multiplex human proinflammatory cytokine panel kit (Meso Scale 
Diagnostics (MSD) was used as per manufacturer instructions. The assay uses an 
MSD MULTI-SPOT® 96-well plate with each well containing 10 separate electrodes 
covered with immobilised capture antibodies for specific cytokines (Figure 2.9). As per 
supplier instructions the MULTI-SPOT® plate was washed thrice with a wash buffer 
(PBS + Tween-20). Samples and calibration controls were added to respective wells 
and incubated on a plate shaker (Cole-Parmer) for 2 hours to allow cytokines to bind 
with immobilised antibodies. Plates were washed thrice again with wash buffer and 
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detection antibodies (with the exception of IL-8) were added to each well. Plates were 
incubated for a further 2 hours. Excess detection antibodies were removed by washing 
the plates thrice with wash buffer. Wells were topped up with a read buffer (MSD) and 
the plates were analysed using a QuickPlex multiplex plate reader (MSD). The plate 
reader applies a voltage to each electrode which, when combined with the read buffer 
results in electrochemiluminescence. The instrument used the intensity of transmitted 
light to calculate a quantitative measure of each cytokine. Supernatants were analysed 
in biological triplicates. 
2.13 Statistical Analysis 
Statistical analysis was carried out using GraphPad Prism version 8. Analysis of the 
quantified cytokine levels were conducted in biological triplicate (N=3) using repeated 
measures one-way ANOVA with Bonferroni correction. P values of <0.05 were 
considered statistically significant. 
  
Figure 2.10. MSD MULTI-SPOT® electrode arrangement. Each electrode surface 
contains immobilised capture antibodies for specific cytokines. The cytokines bind to 
the capture antibodies and in turn bind detection antibodies which are conjugated to 




Chapter 3 Optimisation of a Handmade 24-well Skin Equivalent 
3.1 Introduction 
In this chapter the 24-well based full-thickness Skimune3D® human skin equivalent 
(HSE) was optimised using primary human skin cells and compared to human skin. 
The Skimune3D® HSE was originally developed in a 6-well format by Hill et al and 
adapted for use with 24-well transwell inserts by Alcyomics (Hill et al. 2015). The format 
of the Skimune3D® HSE was reduced further to decrease the number of cells required 
per HSE and to increase the number of HSEs that could be developed per donor. This 
chapter explores the reproducibility of the established 24-well HSE. The 24-well HSEs 
were then optimised by investigating the impact of fibroblast numbers to improve the 
development of both the dermal and the epidermal layers. The structure of the 
optimised HSEs were stained using basic histological and immunohistological 
techniques to visualise dermal extra-cellular matrix (ECM) and epidermal 
differentiation markers. Finally, the HSEs were compared to human skin biopsies to 
determine if Skimune3D® was physiologically representative of human skin. 
3.2 Aims  
1. Reproduce and optimise the 24-well Skimune3D® HSE using primary cells 
isolated from human skin. 
2. Analyse the structure of the handmade HSEs to detect dermal and 
epidermal markers. 
3. Compare the physiology of the HSEs to that of physiological human skin. 
3.3 Results 
3.3.1 Skin equivalents made with the 24-well Skimune3D® protocol 
As initially established by protocol provided by Alcyomics, the 24-well based HSEs 
were first produced with a 1:1 ratio of fibroblasts and keratinocytes. Haematoxylin and 
eosin (H&E) staining provided an insight into the extent of HSE development and 
variation from donor to donor. The HSEs were made with the established protocol 
using 1x106 fibroblasts and 1x106 keratinocytes from several donors (n=6). The 
resulting HSEs developed did not form successfully with a similar issue occurring in 
each HSE to various degrees.  
It was observed in some donors that the dermal compartment had completely failed to 
form and was sparsely populated with fibroblasts (Figure 3.1). Donor 1 produced a 
layer of fibroblasts which lined the underside of the Alvetex® scaffold, however no 
54 
 
fibroblast layer was observed at the top of the scaffold. The poorly formed dermis 
formed by donor 1 resulted in the infiltration of keratinocytes into the Alvetex® scaffold 
and therefore no epidermal layer was observed. Donor 2 also failed to form a dermis 
with no fibroblast layer visible above or beneath the scaffold and subsequently no 
epidermal layer. Few fibroblasts were seen within the scaffold which mostly appeared 
to contain differentiating keratinocytes. Additionally, donor 3 did not form a complete 
dermis, or an epidermis and few fibroblasts were visible in the scaffold. Once again, 
the scaffold was populated with differentiating keratinocytes. Donor to donor variation 
resulted in some HSE’s which had partially formed (Figure 3.2). Both donors 4 and 5 
partially developed a dermis and an epidermis. However, the incomplete dermis 
resulted in some fall through of keratinocytes into the scaffolds. No basal strata could 
be seen in donors 4 and 5 although spinous and granular strata were visible. Donor 6 
also partially formed a dermis however epidermal development was poor, only a partial 
corneal envelope was present. Overall, the data showed that the use of one million 
fibroblasts largely resulted in complete or partial failure of the fibroblasts to form a 





Figure 3.1 H&E staining of HSEs produced with the original protocol using cells 
from donor 1-3. Blue arrows show fibroblasts within the Alvetex® while red arrows 









Figure 3.2 H&E staining of HSEs produced with the original protocol using cells 
from donor 4-6. Blue arrows show fibroblasts within the Alvetex® while red arrows 






3.3.2 Optimisation of dermal development 
It was hypothesised that an increase in the number of dermal fibroblasts would 
increase the amount of ECM produced and improve the formation of the dermal 
equivalent. The numbers of fibroblasts seeded per model were investigated using 
0.5x106, 1x106, 1.5x106 and 2x106 fibroblasts. The dermal equivalents were developed 
for up to 28 days. 1x106 keratinocytes were added on to the dermal equivalents to 
allow epidermal formation and cultured as per the previous protocol. Three 
independent experiments were performed. 
To observe the overall structure of the HSEs, sections of 3 additional donors (7, 8 and 
9) were stained with H&E. Figure 3.3A shows the H&E staining of the full thickness 
model for donor 7, which contained 0.5x106 fibroblasts and 1x106 keratinocytes. This 
model showed similar issues to the initial protocol, where the dermal development was 
poor, and some keratinocyte infiltration was apparent. As expected, a similar issue was 
observed with the full thickness model which contained 1x106 fibroblasts and 1x106 
keratinocytes (Figure 3.3B). The full thickness model which contained 1.5x106 
fibroblasts and 1x106 keratinocytes shown in Figure 3.3C showed a noticeable 
improvement in the formation of a dermis, however some infiltration of keratinocytes 
was noticeable. Due to the improved dermis development in this model, an improved, 
more organised, and thicker epidermis was visible. This resulted in a more defined 
dermal-epidermal junction. The epidermis showed spinous, granular and cornified 
strata. While there were undifferentiated keratinocytes at the bottom of the epidermis, 
the columnar organisation of typical basal keratinocytes was not visible. The full 
thickness model which contained 2x106 fibroblasts and 1x106 keratinocytes (Figure 
3.3D) showed a complete dermis with no visible keratinocyte infiltration into the dermal 
compartment. The fibroblasts adequately covered the surface of the scaffold and 
produced sufficient ECM to the support keratinocytes allowing improved epidermal 
formation. As a result, a more densely populated epidermal layer was observed which 
was more clearly defined. More undifferentiated keratinocytes were visible resulting in 
a slightly better formation of the basal strata indicated immediately above the black 
dashed line. The epidermis of this model also featured a thicker spinous layer with the 

































































Figure 3.3 H&E staining of HSEs made with cells from donor 7. (A) HSE made with 
0.5x106 fibroblasts and 1x106 keratinocytes. (B) HSE made with 1x106 and 1x106 
keratinocytes. (C) HSE made with 1.5x106 fibroblasts and 1x106 keratinocytes. (D) 




Figure 3.4 shows the H&E staining of the full thickness model for donor 8. Results were 
comparable to those observed for donor 7. Figure 3.4A shows the model containing 
0.5x106 fibroblasts and 1x106 keratinocytes. Poor formation of the dermal layer with a 
large amount of keratinocyte infiltration as observed for donor 7. The HSE containing 
1x106 fibroblasts and 1x106 keratinocytes (Figure 3.4B) showed a similar result to that 
observed in Figure 3.4A, with slightly less keratinocyte infiltration into the dermal layer 
as shown in the initial experiments. The HSE which contained 1.5x 106 fibroblasts and 
1x106 keratinocytes (Figure 3.4C) showed no visible keratinocyte infiltration and much-
improved development of the dermal compartment. There was also improved 
development of the epidermal layer showing a well organised epidermis, with a nicely 
defined dermal-epidermal junction. The epidermis contained a well-developed spinous 
stratum with the early formation of a granular strata visible. In comparison to donor 7, 
donor 8 appeared to form an overall better HSE. The full thickness HSE which 
contained 2x106 fibroblasts and 1x106 keratinocytes produced a well-developed HSE 
as shown in Figure 3.4D. This HSE showed no visible keratinocyte infiltration into the 
dermal compartment. The fibroblasts adequately covered the surface of the scaffold 
and produced enough ECM to support the keratinocytes resulting in a clear dermal-
epidermal junction, allowing epidermal formation. Notably, the increase in fibroblasts 
in the dermis from 1.5x106 cells to 2x106 cells appeared to result in a thicker epidermis, 
this was also observed in donor 7. A good columnar organisation of basal keratinocytes 
provided a self-renewing population of keratinocytes within the epidermis.  As a result, 
a more densely populated epidermal layer was observed which was more clearly 
defined. More undifferentiated keratinocytes were visible resulting slightly better 
formation of the basal strata visible immediately above the black dashed line. The 
epidermis of this HSE also featured a thicker spinous layer with the presence of 

































































Figure 3.4 H&E staining of HSEs made with cells from donor 8. (A) HSE made 
with 0.5x106 fibroblasts and 1x106 keratinocytes. (B) HSE made with 1x106 and 1x106 
keratinocytes. (C) HSE made with 1.5x106 fibroblasts and 1x106 keratinocytes. (D) 




The full-thickness HSEs made with cells from donor 9 are shown in Figure 3.5. The 
HSE made with 0.5x106 fibroblasts and 1x106 keratinocytes showed a low number of 
fibroblasts within the scaffold (Figure 3.5A). As a result, no fibroblasts-ECM layer was 
visible at the top of the scaffold, which caused keratinocytes to infiltrate the dermis. 
Figure 3.5B shows the HSE developed with 1 x106 fibroblasts and 1x106 keratinocytes. 
The dermis partially formed with an inconsistent fibroblast-ECM layer supporting some 
keratinocytes, large pockets of the dermis displayed keratinocyte infiltration. 
Interestingly those keratinocytes that did not infiltrate the dermis appeared to partially 
form the basal strata featuring columnar keratinocytes. The use of 1.5x106 fibroblasts 
and 1x106 keratinocytes (Figure 3.5C) showed partial dermal formation with some 
keratinocytes infiltrating the dermis and some epidermal formation. The full thickness 
HSE shown in Figure 3.5D contained 2x106 fibroblasts and 1x106 keratinocytes. This 
HSE formed a fully developed dermis featuring a fibroblast-ECM layer lining the 
dermal-epidermal junction with no keratinocyte infiltration of the dermis. This allowed 
the dermis to support the keratinocytes facilitating epidermal formation. Clear columnar 
organisation of basal keratinocytes suggested good formation of a basal strata. Some 
stratification could be observed with a spinous layer of differentiating and flattening 
keratinocytes directly above the undifferentiated stratum basale. Partial formation of 
the stratum granulosum could be observed with some granulated cells above the 
































































Figure 3.5 H&E staining of HSEs made with cells from donor 9. (A) HSE made with 
0.5x106 fibroblasts and 1x106 keratinocytes. (B) HSE made with 1x106 and 1x106 
keratinocytes. (C) HSE made with 1.5x106 fibroblasts and 1x106 keratinocytes. (D) HSE 




To visualise dermal extracellular matrix, HSEs were stained with Picro-Sirius Red, 
which is a specific stain for collagen (Figure 3.6). Sirius red stains collagen red while 
staining cell nuclei and cytoplasm yellow. The stain allowed qualitative insight into the 
extent of ECM being produced by the dermal fibroblasts. The production of ECM is 
critical to the formation of a complete dermal equivalent. Inadequate production of 
ECM resulted in a porous dermal substrate preventing keratinocytes forming a 
complete monolayer on top of the dermis. Therefore, poor ECM production could 
directly affect epidermal formation. The staining showed poor ECM production and 
dermal formation in Figure 3.6A (0.5x106 fibroblasts) and 3.6B (1x106 fibroblasts). By 
increasing the number of fibroblasts to 1.5x106 there was a visible improvement in 
ECM production and dermal development (Figure 3.6C). HSE’s made with 1.5x106 
fibroblasts showed improved formation of a collagen mesh (black arrow) at the top of 
the Alvetex® scaffold. This allowed partial epidermal development, however, 1.5x106 
fibroblasts still resulted in a patchy dermal equivalent with a lack of collagen in some 
regions resulting in infiltration of keratinocytes into the dermal compartment. Figure 
3.6D shows that a further increase of fibroblasts to 2x106 resulted in a complete 
collagen mesh formation at the dermal epidermal junction indicated by the red staining 
(black arrow). This provided the keratinocytes with a solid foundation to form an 
epidermis without cells falling into the dermal equivalent. The yellow staining above 
the dermis represents staining of epidermal keratinocytes which have not fallen into 
the dermal equivalent resulting in the full thickness HSE. Overall, 100% of HSEs 
































































Figure 3.6 Picro-Sirius Red staining of HSEs made with a range of 
keratinocytes. A) HSE made with 0.5x106 fibroblasts and 1x106 keratinocytes. 
(B) HSE made with 1x106 and 1x106 keratinocytes. (C) HSE made with 1.5x106 
fibroblasts and 1x106 keratinocytes. (D) HSE made with 2x106 fibroblasts and 
1x106 keratinocytes. Cell cytoplasm and nuclei were stained yellow while collagen 




3.3.3 Comparison of histological techniques 
The titration of antibodies specific for human cytokeratin 10 and human loricrin using 
sections of physiological human skin are shown in Figure 3.7 and Figure 3.8, 
respectively. Titration of rabbit anti-human cytokeratin 10 showed that the primary 
antibody was highly specific for human epidermal cytokeratin 10 as staining was highly 
localised at the spinous and granular strata of the epidermis. Titration of the rabbit anti-
human loricrin antibody showed specificity for the stratum corneum of the epidermis in 
physiological human skin. Whilst use of the primary antibody at a 1:125 dilution yielded 
limited expression due to peeling of the stratum corneum during sectioning, loricrin 
could be identified in the epidermis of other concentrations. 
Staining of dermal collagen type III in physiological human skin using a mouse anti-
human is shown in Figure3.9. At a concentration of 1:250 some staining could be 
observed in the dermis of the human skin however the staining was limited. Staining 
was also observed in the epidermis of the skin which was not expected. When the 
concentration of the primary antibody was increases to 1:125 the extent of staining in 
both the dermis and epidermis increased. 
Immunofluorescent staining for the basement membrane at the dermal-epidermal 
junction of human skin in by staining for collagen IV, collagen VII and laminin-5 are 
shown in Figure 3.10, Figure 3.11, and Figure 3.12, respectively. As concentration of 
the mouse anti-human collagen IV antibody increased so did the expression within the 
dermal region of the human skin (Figure 3.10). However, despite this increasing 
expression specific staining of the basement membrane at the dermal-epidermal 
junction was not detected in human skin. A similar trend was seen when staining for 
dermal collagen VII in human skin where an increase in concentration resulted in 
increasing staining in the dermis yet there was no specific staining of the basement 
membrane structure. (Figure 3.11). Laminin-5 staining was conducted with a wide 
range of concentrations most of which did not produce any staining (Figure 3.12). 
Staining at a high concentration of 1:25 produced expression in the dermis. This 
expression was mostly located in the upper dermis but was not specific for the 




 Figure 3.7 Titration of rabbit anti-human cytokeratin-10 antibody using 
physiological human skin. Cytokeratin-10 is shown in red. Hoechst nuclear 





Figure 3.8. Titration of rabbit anti-human loricrin antibody in physiological 






Figure 3.9. Immunofluorescent staining for collagen III using physiological 







Figure 3.10 Immunofluorescent staining of basement membrane collagen IV in 
physiological human skin. Collagen IV is shown in green. Hoechst nuclear 




Figure 3.11. Immunofluorescent staining of basement membrane collagen VII in 
physiological human skin. Collagen VI is shown in green. Hoechst nuclear 




Figure 3.12. Immunofluorescent staining of basement membrane laminin-5 in 
physiological human skin. Laminin-5 is shown in red. Hoechst nuclear staining 




3.3.4 Histological comparison of skin equivalents to physiological human skin 
To determine if the HSEs were representative of physiological human skin, human skin 
biopsies were paraffin embedded, sectioned, and stained with H&E and Picro-Sirius 
Red for histological analysis. The skin biopsies (Figure 3.13) showed two very clearly 
defined layers (dermis and epidermis) which were separated by a dermal/epidermal 
junction (dotted line) as seen in Figure 3.13A.  The epidermis of the human skin 
contains stratified sublayers which were also visible in the skin equivalents optimised 
with 2x106 fibroblasts and 1x106 keratinocytes as shown previously, which indicates 
that the development of the HSEs were representative of human skin. 
The physiological human skin was also stained with Picro-Sirius Red. The Picro-Sirius 
Red staining revealed two sublayers of the dermis, the papillary dermis and the 
reticular dermis separated by the blue dashed line (Figure 3.13B). The papillary dermis 
in human skin contains smaller and thinner collagen fibres (Rognoni and Watt 2018) 
much like those seen in the optimised full thickness HSE’s suggesting that the dermis 
formed in the HSE’s is more physiologically representative of the papillary dermis. The 
collagen in the reticular dermis in human skin was observed to consist of much larger, 
more organised and cross-linked collagen resulting in reticular connective tissue 
(Rognoni and Watt 2018). This was shown by the larger areas of strong red staining in 
the reticular dermis. Such organised reticular ECM, consisting of larger collagen fibres 
were not seen in the full thickness HSE’s, further indicating that the dermis of the HSE’s 
were more representative of the papillary dermis. This shows that the HSE’s were 
therefore physiologically accurate.  
To compare the development of the basement membrane in HSE’s to physiological 
human skin, periodic acidic Schiff staining was performed. Periodic acidic Schiff stains 
the glycoproteins found within the basement membrane a magenta colour whilst 
staining cells dark blue. Figure 3.14A shows the magenta staining representing the 
glycoproteins in the basement membrane of physiological human skin at the dermal-
epidermal junction. This membrane is shown to be present directly underneath the 
basal strata of the epidermis. In the HSEs (Figure 3.14B) the presence of fibroblasts 
lining the dermal epidermal junction directly beneath the basal keratinocytes resulted 
in a strong dark blue stain with some traces of the magenta stain representing the 
basement membrane visible between the two layers of the HSE. However, the large 
population of both fibroblasts and keratinocytes at the dermal/epidermal junction 
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resulted in dark blue staining at the dermal-epidermal junction which could have 










Figure 3.13 Representative histology images of staining of normal healthy 
human skin. (A) H&E of a normal human skin biopsy. Black dotted line indicates 
the dermal-epidermal junction. (B) Picro-Sirius Red staining of a normal human 
skin biopsy. Black dotted line indicates the dermal-epidermal junction. Blue 






Figure 3.14. Representative images for Periodic Acidic Schiff staining of both a 
healthy human skin biopsy and a fully formed full-thickness HSE. (A) Human skin 
biopsy. (B) Optimised full-thickness HSE. 
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Physiological human skin and the HSEs were stained for elastin using Verhoeff van-
Geison staining. The Verhoeff van-Geison stains cell nuclei black, cytoplasm brown, 
ECM pink and elastin fibres black. In physiological human skin, elastin fibres in the 
dermal region close to the epidermis (papillary dermis) were shown to be small and 
thin grey fibres which are difficult to detect (Figure 3.15B). These fibres become larger 
and thicker with darker staining further into the reticular dermis. These elastin fibres 




Figure 3.15 Representative histology images of Verhoeff van-Geison staining of 
both a physiological human skin (A) and HSE  (B). 
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Immunofluorescent staining was used to stain different markers present throughout 
various strata of the epidermis in both physiological human skin (Figure 3.16) and 
HSE’s (Figure 3.17). In the basal strata of the epidermis in physiological human skin, 
basal keratinocytes which are healthy, proliferating, and undifferentiated contain 
cytokeratin 14 (Figure 3.16A), which is an intermediate filament within the cytoskeleton 
of basal keratinocytes. Positive staining for cytokeratin 14 indicates keratinocytes with 
a basal phenotype were present. In the HSE’s, cytokeratin 14 was also detected 
(Figure 3.17A) directly above the dermal/epidermal junction (dashed line). As the 
keratinocytes begin to differentiate and stratify, they begin to express cytokeratin 10, 
which also is a component of the cytoskeleton. Cytokeratin 10 is expressed in the 
spinous and granular strata in the epidermis of physiological human skin. In 
physiological human skin, cytokeratin-10 (Figure 3.16B) was present above the basal 
strata of the epidermis. Cytokeratin 10 was also detected above the basal layer in the 
HSE’s (Figure 3.17B). Involucrin, a precursor of the stratum corneum is found in the 
granular and upper spinous strata. Both physiological skin and the HSE’s expressed 
involucrin in the spinous and granular strata (Figure 3.16C and Figure 3.17C). Loricrin 
is present in the corneal envelope of the epidermis and in the human skin it was found 
to be in the uppermost strata of the epidermis (Figure 3.16D). In the HSE’s, the loricrin 
staining was positively detected, however, it was not as clearly defined as that 
observed in physiological human skin due to artefact during tissue processing (Figure 
3.17D).  The null primary images (negative controls) for immunofluorescent staining 




Figure 3.16. Representative images of human skin biopsies stained with 
immunofluorescent staining. (A) Cytokeratin 14 (green) staining of human skin. (B) 
Cytokeratin 10 (red) staining of human skin. (C) Involucrin (red) staining of human skin. 
(D) Loricrin (red) staining of human skin. White dashed line indicates dermal-epidermal 





Figure 3.17. Representative images of HSEs stained with immunofluorescent 
staining. (A) Cytokeratin-14 (green) staining of HSE. (B) Cytokeratin-10 (red) staining 
of HSE. (C) Involucrin (red) staining of HSE. (D) Loricrin (red) staining HSE. White 





Figure 3.18. Null primary images (negative controls) from immunofluorescent 
staining of human skin equivalents.  
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To minimise the incubation time and cost of additional antibody diluent and washing 
buffer (~£1.50 per slide) associated with evaluating the HSE’s for differentiation 
markers immunofluorescence double staining was established using two different 
combinations of antibodies. Figure 3.19 shows staining for Involucrin and cytokeratin 
14 in both human skin (Figure 3.19A) and HSE (Figure 3.19B). Performing the double 
stain on a single section more clearly defines the separate layers of the epidermis and 
gives a better outline and a more direct comparison of the formation of the different 
sublayers of the epidermis. 
  
Figure 3.19. Representative images of double immunofluorescent staining for 
cytokeratin-14 and Involucrin in human skin biopsies and HSEs. (A) Staining of 
human skin biopsy. (B) Staining of HSE. White dotted line indicates dermal-epidermal 




The initial 24-well format Skimune 3D® protocol provided by Alcyomics yielded models 
which did not fully develop, the histological analysis of each model suggested the same 
cause of failure. While the extent of development varied from donor to donor, each 
donor demonstrated insufficient cell numbers and ECM production to prevent the fall 
through of keratinocytes into the dermal equivalent. Therefore, the tissues formed were 
not physiologically accurate as there was no reproducible formation of a dermis and a 
separate epidermal layer with relevant strata. To form a well-developed dermis, 
sufficient cell numbers and ECM would be required to plug the pores of the inert 
Alvetex® scaffold thereby blocking any keratinocytes from entering the scaffold. This 
could be achieved in two ways; firstly, by increasing the number of dermal fibroblasts 
seeded; and secondly, by encouraging an increase in proliferation or ECM production 
by adjusting the contents of the dermal culture media. The Skimune 3D® model relies 
on ascorbic acid to encourage dermal fibroblasts to produce ECM (Hill et al. 2015). 
Collagen is one of the main components in the ECM of human skin with collagen type 
I making up to 85-90% of total collagen, while collagen type III comprises of 8-11% of 
total collagen (Smith, Holbrook, and Madri 1986). While ascorbic acid has been shown 
to increase proliferation of dermal fibroblasts, ascorbic acid also specifically 
upregulates collagen type I and type III synthesis by increasing the synthesis of 
precursor collagen chains proα1(I) and proα1(III) (Hata et al. 1988; Phillips, Combs, 
and Pinnell 1994). To further encourage ECM production, the use of additional growth 
factors such as transforming growth factor beta 1 (TGF-β1) was considered. The 
effects of TGF-β1 on the proliferation and ECM synthesis of dermal fibroblasts has 
been well documented (Chen and Thibeault 2012; Grouf et al. 2007; Phillips, Combs, 
and Pinnell 1994). TGF-β1 increases the proliferation of dermal fibroblasts and the 
synthesis of dermal ECM by increasing overall protein synthesis (Phillips, Combs, and 
Pinnell 1994). However more recently the use of TGF-β1 has been shown to alter the 
phenotype of dermal fibroblasts. TGF-β1 has been implicated in the lineage 
reprogramming (trans-differentiation) of dermal fibroblasts to myofibroblasts by 
upregulation of microRNA-21 (miR-21) (Liu et al. 2016; Midgley et al. 2013). TGF-β1 
induced trans-differentiation of fibroblasts to myofibroblasts is a factor in the formation 
of scar tissue (Midgley et al. 2013). Therefore, the use of TGF-β1 in developing the 
dermal equivalent may result in a dermal equivalent containing ECM like that of keloid 
scar tissue with the presence of myofibroblasts and therefore be less physiologically 
representative of normal healthy human skin.  
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The introduction of additional growth factors into the media would also influence the 
development cost of Skimune3D®. It was therefore determined that rather than adding 
additional growth factors to improve dermal development, investigating how increasing 
the number of fibroblasts initially seeded into the scaffold would impact the formation 
of the dermal equivalent could be more economically beneficial for development costs. 
By doubling the number of dermal fibroblasts seeded initially from 1x106 to 2x106 the 
production of a dermal equivalent was shown to be robust and reproducible across 
donors. The variability of the proliferative capacity and ECM synthesis of dermal 
fibroblasts was highlighted by equivalents using 1.5x106 fibroblasts which produced 
variable results. Of the three donors used, only two donors developed a dermis with 
1.5x106 fibroblasts capable of supporting keratinocytes with little or no epidermal 
infiltration into the dermis. The same donors also demonstrated the impact that number 
of fibroblasts can have on keratinocyte proliferation. An increase in epidermal 
thickness and improved epidermal development was seen when the number of 
fibroblasts was increased from 1.5x106 to 2x106. The improved stratification and thicker 
epidermis of equivalents made with 2x106 fibroblasts compliments the findings of 
previous studies (el-Ghalbzouri et al. 2002; Sun et al. 2008; Wang et al. 2012). The 
increase in fibroblasts may well have resulted in increased cell-cell contact and cross-
talk between the fibroblasts and keratinocytes, thereby resulting in overall 
improvement in HSE formation. As reported by Wang et al an increase in direct 
fibroblast-keratinocyte contact can increase the proliferation of keratinocytes (Wang et 
al. 2012). The increasing intensity of red PSR staining of skin equivalents suggested 
that increasing the number of fibroblasts initially seeded appeared to affect the extent 
to which collagen type I and type III was produced within the scaffold. Thinner collagen 
fibres were visible within and underneath the dermal component. Interestingly the 
collagen located at the surface of the scaffold (dermal-epidermal junction) suggested 
the presence of more compact collagen. This could be explained by the high number 
of fibroblasts present at the dermal-epidermal junction. Evidently without an adequate 
cell-ECM layer at the dermal-epidermal junction skin equivalents failed to form. Overall 
optimal dermal and epidermal development occurred when seeding 2x106 fibroblasts 
consequently forming full-thickness skin equivalents which were highly comparable to 
physiological human skin. 
In healthy normal human skin, the epidermis and the dermis are separated by a 
basement membrane at the dermal-epidermal junction. This feature was not detected 
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when using immunofluorescence to stain for basement specific proteins such as 
collagen IV, collagen VII, and laminin-5 due to the lack of specificity of the primary 
antibodies. In contrast the basement membrane was positively detected in skin 
biopsies by staining for glycoproteins using periodic acid-Schiff PAS. In skin 
equivalents PAS staining was inconclusive. The columnar organisation of basal 
keratinocytes in H&E stained sections appeared to suggest the formation of a 
basement membrane however only very subtle traces of glycoproteins were visible 
when stained with PAS. The high density of dark blue stained dermal fibroblasts at the 
dermal-epidermal junction may have masked the PAS staining of the basement 
membrane glycoproteins.  Analysis of elastin in skin equivalents using Verhoeff–Van 
Gieson staining, revealed no visible production of elastin fibres as the fibroblasts were 
supplemented with ascorbic acid to promote collagen synthesis, rather than increase 
general protein synthesis. In human skin biopsies a gradient of elastin fibres was 
observed with very little to no elastin fibres in the papillary dermis and fibres increasing 
in number and size further into the reticular dermis. When comparing the elastin 
content of the skin equivalents to healthy human skin the HSEs appeared to more 
closely represent the papillary dermis than the reticular dermis suggesting that the 
dermal compartment of skin equivalents was physiologically accurate. 
Epidermal differentiation and stratification were characterised by the detection of 
cytoskeletal keratins, a cornified envelop precursor and a marker of a cornified 
envelope by immunofluorescent staining. The detection of cytokeratin-14 directly 
above the dermal-epidermal junction confirmed the formation of a basal strata 
containing healthy undifferentiated “stem cell” like keratinocytes. Suprabasal 
expression of cytokeratin-10 and involucrin indicate a layer of keratinocytes in the 
process of undergoing terminal differentiation above the basal strata much like 
epidermal formation in physiological human skin. The combined staining of cytokeratin-
14 and involucrin demonstrated epidermal stratification in skin equivalent. Suprabasal 
detection of loricrin in skin equivalents suggested the presence of a cornified envelope 
in the epidermis. 
Overall, this chapter demonstrates importance of optimising cell numbers and seeding 
ratios by increasing the number of fibroblasts used to form the dermal compartment of 
the HSE. The amount of ECM produced could be increased by increasing cell numbers 
allowing an improvement in dermal formation which in return resulted in prevention of 
keratinocyte infiltration into the dermal layer. This further resulted in a better and more 
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complete formation of an epidermal layer allowing an overall more physiologically 
relevant HSE to be produced. When compared to the work of Hill et al (Figure 3.20) 
the optimised 24-well HSE presented in this chapter was physiologically similar to the 
original Skimune3D® HSE first developed by Hill et al (Hill et al. 2015). Both the 24-
well HSE and the original HSE feature a bilayer construct with a densely populated 
dermis and a stratified epidermis. 
To improve the scalability of the Skimune3D® HSE the next iterations of the HSE would 
require a reduction in size to facilitate the reduction in the number of cells necessary 
to construct HSEs using primary human skin cells. This would require a reduction in 
format from the 24-well transwell system presented in this chapter. 
  
Figure 3.20. Comparison of original Skimune to optimised 24-well skin 
equivalents. A) Original 6-well HSE developed by Hill et al (adapted from Hill et al 
2015), Scale bar: 100μm. B) Handmade 24-well HSE, scale bar: 100μm. 
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Chapter 4 Development of a Handmade 96-well Skin Equivalent 
4.1 Introduction 
In this chapter human skin equivalents (HSEs) were scaled to the 96-well format using 
prototype transwell inserts. The rationale for scaling HSEs to the 96-well format was to 
minimise the number of cells that would be required to manufacture HSEs and to 
maximise the number of HSEs that per could be produced per healthy donor. This 
chapter describes the work to establish a handmade 96-well HSE by first establishing 
a protocol for manufacturing a dermal equivalent then proceeding to use dermal 
equivalents to create full-thickness HSEs. The structure of the optimised HSEs were 
stained using basic histological and immunohistological techniques to visualise dermal 
extra-cellular matrix (ECM) and epidermal markers. 
4.2 Aims 
The aims of the work described in this chapter were: 
1. Establish a protocol for creating a 96-well format dermal equivalent. 
2. Develop a 96-well full-thickness skin equivalent using the dermal equivalent 
protocol. 
3. Use immunohistochemistry to validate the structure of the epidermis. 
4.3 Results 
4.3.1 Developing a 96-well dermal equivalent 
The representative dermal equivalents harvested at day 10 are shown in Figure 4.1. 
The H&E staining of dermal equivalents made with 1x105 dermal fibroblasts showed a 
good distribution of fibroblasts within the Alvetex® scaffold with slightly fewer cells 
being present at the bottom of the scaffold. While cells were distributed through the 
scaffold the cellularity of the scaffold was poor. Thin fibroblast layers were observed at 
both the top and bottom surfaces of the scaffolds. Picro-Sirius Red staining of the 
dermal equivalents made with 1x105 fibroblasts revealed that the fibroblasts had begun 
to produce small uncross-linked collagen fib res as indicated by the faint red staining 
within scaffold. The use of 3x105 fibroblasts resulted in a good distribution of cells 
within the scaffold with a fibroblasts layer at the top and bottom of the scaffold. Small 
traces of collagen were also present when stained with Picro-Sirius Red. Seeding 
5x105 fibroblasts resulted in a large majority of the cells being located near the bottom 
of the scaffold at day 10. The layer of fibroblasts at the bottom of the scaffold was 
thicker with several layers of cells visible, however, the fibroblast layer at the top of the 
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scaffold was incomplete with visible gaps between cells. No collagen was visible when 
stained with Picro-Sirius Red. Dermal equivalents made with 7x105 fibroblasts were 
densely populated. Most of the dermal fibroblasts were located at the bottom of the 
scaffold where a thick fibroblast layer was noticeable. No collagen was visible in dermal 






















H&E Picro-Sirius Red 
Figure 4.1. Representative dermal equivalents grown for 10 days stained with 
H&E and Picro-Sirius Red. Dermal equivalents incubated for 10 days and stained 
with both H&E to show the location of cells and Picro-Sirius Red to visualise dermal 
collagen. Dermal equivalents were also cultured with a range of dermal fibroblasts 
which include 1x105, 3x105, 5x105 and 7x105 cells. Scale bars: 100µm. 
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Representative H&E and Picro-Sirius Red staining of dermal equivalents incubated for 
14 days can be seen in Figure 4.2. The dermal equivalents made with 1x105 fibroblasts 
maintained a good distribution of cells within the scaffold however the scaffold was still 
thinly populated. A fibroblast layer at the top and the bottom of the scaffold were still 
visible. Picro-Sirius Red staining revealed a noticeable increase in dermal collagen. 
The collagen staining at day 14 was slightly stronger than those observed at day 10, 
with the collagen appearing more complete fewer gaps in the extracellular space, 
particularly in the fibroblast layer at the top and the bottom of the scaffold. While there 
was a complete cell layer at the top of the scaffold the formation of a collagen mesh 
was not complete as there were many regions where fibroblasts had not yet produced 
collagen.  H&E staining of dermal equivalents made with 3x105 fibroblasts revealed 
that most fibroblasts were present at the bottom of the scaffold which contained a thick 
fibroblast layer. The layer of fibroblasts at the top of the scaffold remained thin with 
some gaps between cells observed. The collagen stained with Picro-Sirius Red was 
observed more strongly stained indicating the presence of more collagen which 
appeared to be largely unorganised. Darker red staining at the bottom of the scaffold 
suggested the presence of cross-linked collagen. Conversely the collagen at the top 
of the scaffold was observed to consist of rather thinly distributed indicating that a 
collagen mesh had not formed at the top of the scaffold. As expected, the 
representative H&E of dermal equivalents containing 5x105 fibroblasts was more 
densely populated. A good layer of dermal fibroblasts was observed at the top of the 
scaffold with a thicker fibroblast layer present at the bottom of the scaffold. The 
collagen staining displayed thick reticular like collagen at the bottom of the scaffold 
with less intensely stained collagen within the scaffold. Thicker layers of collagen were 
also observed at the top of the scaffold partially forming a collagen-cell mesh although 
some gaps were observed. The cells in dermal equivalents made with 7x105 were 
shown to be mostly located at the bottom of the scaffold with some cells located 
towards the middle of the scaffold. Some fibroblasts were visible at the top of the 
scaffold though there were not enough cells to create a layer at the top of the scaffold. 
Picro-Sirius Red staining of the scaffold showed very little red staining, indicating that 
there was there was very little collagen present within the scaffold. The faint red of 





















H&E Picro-Sirius Red 
Figure 4.2 Representative dermal equivalents grown for 14 days stained with 
H&E and Picro-Sirius Red. Dermal equivalents incubated for 14 days and stained 
with both H&E to show the location of cells and Picro-Sirius Red to visualise dermal 
collagen. Dermal equivalents were also cultured with a range of dermal fibroblasts 




Representative H&E and Picro-Sirius Red staining of dermal equivalents incubated for 
18 days are shown in Figure 4.3. By day 18 dermal equivalents had developed with 
various states of collagen production. 1x105 fibroblasts produced a dermal equivalent 
with a good distribution of cells throughout the scaffold and a thin layer of fibroblasts 
was observed at the top of the scaffold. When stained with Picro-Sirius Red there was 
a noticeable increase in dermal collagen. Stained collagen was present throughout the 
scaffold with the light red staining suggesting that most of the dermal ECM was not 
cross-linked. Small areas of darker staining were noticeable at the top and the bottom 
of the scaffold indicating that crosslinking of collagen had occurred in these regions, 
however cross-linked collagen was not consistent across the top of the scaffold. 
Dermal equivalents made with 3x105 fibroblasts resulted in most of the cells being 
present at the bottom of the scaffold at day 18. Some cells were visible in the middle 
of the scaffold with a layer of fibroblasts visible at the top of the scaffold. When stained 
with Picro-Sirius red slight thickening of the collagen at the top of the scaffold was 
visible. The inner scaffold appeared more densely packed with collagen compared to 
earlier time points. Some thickening of collagen at the bottom of the scaffold was 
observed. Dermal equivalents containing 5x105 fibroblasts were well populated. A thick 
layer of fibroblasts was visible at the bottom of the scaffold with cells appearing to 
migrate superficially through the scaffold. The fibroblasts had formed a monolayer at 
top of the scaffold. A good layer of collagen was present at the top of the scaffold with 
well stained ECM lining the top of the Alvetex®. Large layers of collagen were stained 
at the bottom of the scaffold where most of the cells were located. After 18 days of 
incubation, dermal equivalents made with 7x105 fibroblasts showed a large outgrowth 
of cells from underneath the scaffold could be seen. Within the outgrowth a large layer 
of cells could be seen with irregular morphology. The fibroblasts appeared swollen with 
larger nuclei much like cells to undergoing necrosis. Inside the scaffold the fibroblasts 
were mostly located in the lower regions. A layer of fibroblasts was found to be present 
at the top of the scaffold although some gaps were visible. Very little collagen 
production in the scaffold was observed when stained with Picro-Sirius Red. A thin and 
patchy layer of collagen lined the top of the scaffold while very little collagen was visible 






Figure 4.3. Representative dermal equivalents grown for 18 days stained with 
H&E and Picro-Sirius Red. Dermal equivalents incubated for 18 days and stained 
with both H&E to show the location of cells and Picro-Sirius Red to visualise dermal 
collagen. Dermal equivalents were also cultured with a range of dermal fibroblasts 
which include 1x105, 3x105, 5x105 and 7x105 cells. Scale bars: 100µm. 
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4.3.2 Developing a 96-well full-thickness skin equivalent 
H&E staining of dermal equivalents constructed with 3x105 and 5x105 fibroblasts and 
seeded with keratinocytes are shown in Figure 4.4. The use of 3x105 fibroblasts in 
dermal equivalents resulted in complete infiltration of epidermal keratinocytes into the 
dermal compartment. As shown in Figure 4.4 all the 3x105 dermal equivalents seeded 
with 1x105, 3x105, 5x105 or 7x105 keratinocytes were unable to support the formation 
of an epidermis without infiltrating keratinocytes. 
H&E stained skin equivalents constructed using 5x105 fibroblasts and keratinocytes 
are shown in Figure 4.5. Skin equivalents seeded with 1x105 keratinocytes developed 
a very thin epidermis with only the granular stratum and the stratum corneum visible. 
There were visible gaps in the epidermis with delamination occurring between the 
layers of differentiated keratinocytes. The dermis was well formed with no visible 
keratinocyte infiltration. Seeding 3x105 keratinocytes produced well-formed skin 
equivalent. The epidermis included a basal layer above the dermal-epidermal junction 
(dotted line) which mostly covered the dermal equivalent with undifferentiated 
keratinocytes, a spinous layer, and a granular layer. The flattened nuclei of 
differentiating keratinocytes could be seen in the spinous strata (black arrow) directly 
above the basal strata, some vacuoles (red arrow) were also visible in the spinous 
strata. The granular layer which separated from the skin equivalent during sectioning 
was visible. The dermal equivalent was well formed with a fibroblast/ECM layer 
supporting the epidermis, there was no visible keratinocyte infiltration into the dermis. 
Skin equivalents containing 5x105 keratinocytes featured a partial basal layer in the 
epidermis above the dermal-epidermal junction (black dotted line). The basal strata 
containing undifferentiated keratinocytes was inconsistent across the dermal 
equivalent. Alongside the columnar undifferentiated basal keratinocytes, were cells 
that were undergoing differentiation with some degree of vacuolisation occurring (blue 
arrow). Directly above the partial basal strata was a consistent but thin spinous stratum 
with some separation visible between the layers of differentiating cells. Above the 
spinous strata was a layer of keratinocytes which appeared to be dyskeratotic (blue 
arrows). This layer of keratinocytes, which adhered poorly to the spinous strata, were 
heavily stained with eosin and contained shrunken pyknotic and hyperchromatic nuclei 
(green arrow). Seeding 7x105 keratinocytes onto dermal equivalents resulted in 
complete infiltration of the dermal equivalent by keratinocytes resulting in failure to form 




Figure 4.4. HSEs developed with 3x105 fibroblasts stained with H&E. Dermal 
equivalents constructed with 3x105fibroblasts were grown for 18 days and seeded 







Figure 4.5. HSEs developed with 5x105 fibroblasts stained with H&E. Dermal 
equivalents constructed with 5x105 fibroblasts were grown for 18 days and seeded 
with 1x105, 3x105, 5x105, and 7x105 keratinocytes. Differentiating keratinocytes are 
shown by the black arrow, Blue arrow points to a dyskeratotic keratinocyte. Green 
arrows indicate pyknotic and hyperchromatic nuclei. Scale bars:100µm. 
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To further improve the overall thickness and cellularity of the epidermis in HSEs the 
number of keratinocytes seeded into the scaffold were increased to 4x105 
keratinocytes while the number of fibroblasts per skin equivalent remained at 5x105. 
HSEs constructed with 4x105 keratinocytes and 5x105 fibroblasts were stained with 
H&E to visualise the overall structure of the HSEs, Picro-Sirius Red to detect dermal 
collagen, periodic acidic-Schiff (PAS) to stain mucosubstances found in basement 
membranes and Verhoeff-van Gieson staining to distinguish any elastin fibres from 
collagen. The representative images of 96-well HSEs made with the final protocol are 
presented in Figure 4.6. The representative H&E staining of HSEs showed two 
separate distinct layers Figure 4.6A. The epidermis was thick with undifferentiated 
keratinocytes forming a sparsely populated basal layer above the dermal-epidermal 
junction (black dotted line). The keratinocytes had migrated superficially while 
differentiating to produce a good stratum spinosum although some vacuoles could be 
seen (back arrow). Above the spinous strata a single layer of granular keratinocytes 
forming the stratum granulosum was visible and consistent across the HSE (red arrow). 
Thin layers of the final layer of the epidermis, the stratum corneum were located directly 
above the stratum granulosum (blue arrow). The stratum corneum appeared to 
delaminate and peel from the epidermis possibly as an artefact of sample processing 
or sectioning. As expected, the Picro-Sirius Red staining of the full-thickness HSE 
(Figure 4.6B) revealed a network of dermal collagen throughout the Alvetex® scaffold 
with thicker layers located at the dermal-epidermal junction and the bottom of the 
scaffold. The cell nuclei and cytoplasm were stained dark orange rather than yellow 
due to over exposure to ethanol during stain differentiation and section dehydration. 
The PAS staining failed to clearly detect any glycoproteins that would constitute a basal 
membrane at the dermal-epidermal junction (Figure 4.6C). When stained for elastin 
using Verhoeff-van Gieson staining (Figure 4.6D), elastin fibres which would stain 




Figure 4.6. Representative staining of Full-thickness HSEs constructed with 
5x105 fibroblasts and 4x105 keratinocytes stained. A) H&E staining of HSE. Black 
dotted line indicates the dermal epidermal junction. Black arrow indicates vacuoles. 
Red arrow indicates granular strata. blue arrow indicates stratum corneum B) Picro-
Sirius red of HSE. C) Periodic acidic-Schiff staining of HSE. C) Period acidic-Schiff 
staining of HSE. D) Verhoeff-van Geison staining of HSE. Scale bars: 100µm. 
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Immunofluorescence staining was used to stain various markers present throughout 
the different strata of the epidermis in handmade 96-well HSEs. Representative 
images of HSEs stained using immunofluorescence as shown in Figure 4.7.  The null 
primary images are shown in Figure 4.8. Cell nuclei were stained blue with Hoechst 
33342. Cytokeratin-14 is a cytoskeletal intermediary keratin filament of healthy 
undifferentiating basal keratinocytes. As shown in Figure 4.7 the lowest strata of the 
epidermis stained positively for cytokeratin-14 directly above the dermal-epidermal 
junction (green stain). HSEs were also stained for Cytokeratin-10. Cytokeratin-10 is a 
cytoskeletal intermediary filament present in keratinocytes undergoing differentiation 
in the spinous and granular strata of the epidermis. In handmade 96-well HSEs 
cytokeratin-10 was detected in the epidermis above of the basal layer (red stain). The 
expression of cytokeratin-10 above the basal keratinocytes confirmed the formation of 
a thin stratum spinosum. Involucrin is precursor of the epidermal corneal envelope and 
is found in the same regions of epidermis as cytokeratin-10. In Figure 4.7 staining 
involucrin (red stain) was detected in the upper strata of the epidermis as expected. In 
healthy human skin loricrin is found in the stratum corneum of human skin. Loricrin 





Figure 4.7. Immunofluorescent staining of handmade 96-well HSEs. Full-thickness 
HSEs made with 5x105 fibroblasts and 3x105 keratinocytes, stained for cytokeratin-14 
(green), cytokeratin-10 (red), Involucrin (red) and loricrin (red). Cell nuclei stained blue 




Figure 4.8. Null primary (negative controls) for immunofluorescent staining of 





Overall, the transition from a 24-well format HSE to a 96-well format HSE required the 
optimisation of the cellularity of the HSEs. As summarised in chapter 3, for a dermal 
equivalent to support an epidermis the production of dermal collagen is vital. Dermal 
development was investigated with the aim of minimising overall lead time and cell 
requirement to maximise output. The production of cross-linked dermal ECM appeared 
to largely occur between days 10 and day 14. The difference in dermal ECM between 
day 14 and day 18 was less noticeable. The key difference between dermal equivalents 
incubated for 14 days and 18 days was the thickening of the cell/ECM mesh at the top 
of the dermal equivalent. While reducing the lead time of the dermal equivalent by 4 
days from 18 to 14 days may slightly reduce product development costs (£0.80 of 
media and supplements per well not including cost of labour), the data suggested that 
seeding keratinocytes at day 14 would not result in a full-thickness skin equivalent and 
therefore was not functional. Evidently the use of lower cell numbers (3x105) to produce 
dermal equivalents also was not feasible. This was due to the lack of ECM production 
at the surface of the scaffold. In contrast HSEs developed with 5x105 fibroblasts 
consistently supported keratinocytes without infiltration of epidermal cells into the 
dermis due to thicker collagen layers lining the top of the dermal equivalents. However, 
the data does suggest that there is some limitation to what dermal equivalents can 
support. HSEs seeded with 7x105 keratinocytes onto the dermis resulted in 
keratinocyte infiltration, while HSEs seeded with fewer keratinocytes did not show this 
to occur. Overall, the general structures of the HSEs were accurate in comparison to 
the 24-well HSE presented in chapter 3. The handmade 96-well HSEs contained the 
relevant epidermal markers supported by a well populated and ECM laden dermal 
equivalent. 
Epidermal formation relies on both a well-formed dermal substrate and the 
establishment of a layer of basal keratinocytes. The basal cells act as stem cells and 
provide a continuous supply of undifferentiated keratinocytes over the two weeks 
required for cornification (Lippens et al. 2005). Interestingly HSEs prepared with 1x105 
keratinocyte were lined with layers of terminally differentiated cells with no available 
basal like cells. Without a self-renewing population of undifferentiated cells, the seeded 
keratinocytes terminally differentiated into corneocytes which adhered poorly to the 
dermis. HSEs made with 3x105 and 5x105 keratinocytes showed marginally improved 
adhesion of corneocytes. Peeling of the epidermis appears more common when there 
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is a lack of a basal layer. As the number of keratinocytes were increased there also 
appeared to be an increase in the number of cells which appeared apoptotic with 
blebbing cytoplasm and hyperchromatic nuclei possibly due to there being too many 
cells seeded onto the dermal equivalents. Additionally, some HSEs also contained 
dyskeratotic bodies. Dyskeratotic keratinocytes are defined as the abnormal or 
premature differentiation of keratinocytes (Kumar et al 2004). Such regions also 
contained eosinophilic cell bodies which were similar in appearance to civatte bodies. 
Civatte bodies are described as being caused by damaged apoptotic basal 
keratinocytes (Pranay, Kumar, and Chhabra 2013). Such features may be the result of 
cells undergoing senescence and apoptosis during three-dimensional (3D culture). 
Overall, the variation in formation of the stratum basale in the epidermis of the HSEs 
reflects the challenges associated with the isolation and culture of primary epidermal 
keratinocytes. While primary fibroblast can be cultured for at least 7 passages and 
maintain their healthy phenotype before the onset of senescence, this is not the case 
for primary keratinocytes. The initial yield of keratinocytes from 4mm punch biopsies is 
low and relies on the early formation of colonies which appears to vary from donor to 
donor. This ultimately comes at the cost of the replicative capacity of the keratinocytes, 
as the longer the cells are in culture the more likely they are to senesce and therefore 
affect the quality of the HSE. To ensure keratinocytes maintain a basal like phenotype 
several studies have explored temporary immortalisation of the keratinocytes through 
incubation with Rho kinase (ROCK) inhibitor Y-27632 (Anderson et al. 2018; Chapman 
et al. 2010; Chapman et al. 2014; Strudwick et al. 2015). This literature indicates that 
the Skimune3D® HSE development process could be improved through the application 
of Y-27632. As a tissue equivalent which is to be routinely developed for commercial 
applications the protocol for Skimune3D® HSEs must also be robust and highly 
reproducible from user to user. 
To date this is not the first skin equivalent to be constructed in a 96-well format. There 
are several reconstituted human epidermis (RHE) equivalents constructed in the 96-
well format which both commercially available (SkinEthicTM RHE from Episkin) a non-
commercial RHEs (Pedrosa et al. 2017). Naturally as RHEs only feature one layer of 
skin it could be argued that such equivalents are less physiologically representative of 
human skin than the HSE presented in the 96-well chapter. In terms of full-thickness 
HSEs in a 96-well format very few have been presented in literature or otherwise. So 
far the only notable full-thickness 96-well HSE Schimek et al (Schimek et al. 2018). 
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Schimek et al used a fibrin gel the create a dermis however the source of the fibrin gel 
was not specified therefore it is unclear if the HSEs produced by Schimek et al were 
autologous (Schimek et al. 2018). In contrast the HSE presented in this chapter were 
fully autologous with the ECM entirely produced by the cells within the HSE. 
When compared to handmade 24-well HSEs presented in chapter 3, the data 
presented in this chapter shows that the number of fibroblasts needed to produce a 
dermis could be reduced by a factor of 4 from 2x106 in the 24-well format to 0.5x106 in 
the 96-well format. The number of epidermal keratinocytes required per scaffold was 
also reduced from 1x106 in the 24-well format to 0.4x106 
Overall, the handmade 96-well HSEs were reproducible across multiple donors and 
representative of human skin, therefore this platform could potentially be used for in-
vitro testing of immunotoxicity. However, there are some practical issues with the 
transwell inserts. Efficiently raising the HSEs to the air-liquid interface without 
damaging the epidermis or leaving residual basal media atop the HSE is more 
technically demanding than for the 24-well system. Additionally, due to the nature of 
the transwell inserts acquiring sections for histology is also difficult as illustrated in 
Figure 2.9 of Chapter 2, section 2.10.2. As the Alvetex scaffold cannot be separated 
from the transwell insert without peeling of the epidermis from the HSE, it was 
necessary to paraffin embed the transwell cradle along with the Alvetex scaffold. The 
processing of multiple models is tedious while sectioning blocks containing plastic 
results in paraffin blocks heating up and microtome blades dulling at a faster rate than 
when sectioning standard tissue. As the paraffin block heats up, the resulting sections 
lose stability causing distortion such as ripples, fold and tears which ultimately 
damages the scaffold and the tissue of interest.  To develop a high throughput assay 
alternative forms of analysis than histology would be necessary as the process of 
individually fixing, dehydrating, paraffin embedding, sectioning, and staining each 
model is both technically demanding and time-consuming.  
To summarise, this chapter presents an iteration of the Skimune3D® HSE which has 
been further scaled down in size to the 96-well format. This scaled down HSE requires 
fewer dermal fibroblasts and epidermal keratinocytes to produce a structure repetitive 
of previous iterations of the technology and of human skin. The combination of fewer 
cells and smaller seeding volumes present a platform which is ideal for solenoid valve 
based bioprinting of HSEs.  
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Chapter 5 Bioprinting of a 96-well Skin Equivalent 
5.1 Introduction 
This chapter establishes the parameters for the bioprinting of human dermal 
equivalents and subsequent bioprinting of human full-thickness skin equivalents. The 
structure of the bioprinted human skin equivalents (HSEs) were stained using basic 
histological and immunohistological techniques to visualise dermal extra-cellular matrix 
(ECM) and epidermal markers. Finally, the functional use of Skimune3D® as a 
predictive in-vitro tool for the identification of immunotoxic therapeutic antibodies was 
assessed by examining cytokine expression. The aims of the work presented in this 
chapter were: 
1. Optimise the bioprinting of skin cells to reproduce the 96-well Skimune3D® 
HSE. 
2. Analyse the structure of the bioprinted HSEs to detect dermal extra-cellular 
matrix (ECM) and epidermal markers. 
3. Investigate the use of Skimune3D® HSEs to detect immunotoxicity of 
monoclonal antibodies in-vitro. 
5.2 Results 
5.2.1 Optimisation of printing parameters 
The volume dispensed per droplet at varying dwell times and positive pressures is 
shown in Figure 5.1. Three main observations can be made: (i) a dwell time of less 
than 100 µs produces no output, (ii) the volume per droplet generally increases with 




Figure 5.1. Mean volume of media dispensed per droplet at varying dwell time 
and positive pneumatic pressure. Dispensing of media at different dwell times and 
back pressures. Error bars represent standard deviation. Some error bars could not be 
shown as they were smaller than the data symbols. 
When printing with a positive pressure of 50mmHg no media was dispensed at a dwell 
time of 100µs. As the dwell time increased the volume per droplet also increased 
peaking at 49.8nl at 600µs. When the dwell time was further increased from 600µs to 
1000µs the mean volume per droplet steadily decreased. At 100mmHg of pressure 
media was not dispensed when printing with a dwell time of 100µs. The droplet volume 
decreased from 200µs to 300µs though steadily increased with the increasing dwell 
time peaking at a volume of 75.7nl per droplet when printing with a dwell time of 
1000µs. Printing with a positive pressure of 150mmHg no droplets were deposited with 
a dwell time 100µs. As the dwell time was increased the mean droplet volume steadily 
increased with little variation except for printing at 300µs. The volume per droplet at 
200mmHg steadily increased from 400µs to 1000µs dwell time with some variability. 
At 250mmHg the mean volume per droplet fluctuated from 400µs to 800µs dwell then 
sharply increased, topping with a mean volume per droplet of 135nl at a dwell time of 
1000µs. The mean volume per droplet at 300mmHg of pressure progressively 
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increased as the dwell time was increased with some variability at 800µs and 900µs 
dwell time. The largest volume dispensed per droplet at 300mmHg was 152nl when 
the dwell time was 1000µs. Increasing the backpressure to 350mmHg was also 
resulted in an increase in the mean volume dispensed per droplet as the dwell time 
was increased however a dip in the volume per droplet was observed at a dwell time 
of 300µs. This trend was also observed when the pressure was increased to 
400mmHg, 450mmHg and 500mmHg with the respective maximum volume per drop 
observed to be 168nl, 189nl and 209.8nl. Overall, the data suggested that a wide range 
of pneumatic pressures and dwell time combinations droplets could be dispensed with 
good consistency. As pressure and dwell time increased increases in standard 
deviation were recorded, suggesting that lower parameters would for a robust and 
reproducible printing process. Statistically parameters printed with 150mmhg were 
some of the most consistent with little standard deviation. Lower pressures were also 
preferred to reduce potential shear stress of cell during printing. Therefore, a pressure 
of 150mmHg and a dwell time of 900µs resulting in a mean volume per droplet of 89.9nl 
was used for the experiments described in the rest of this chapter.  
5.2.2 Bioprinting of dermal fibroblasts 
A study was designed to explore the capacity of the modified bioprinter to print a cell 
laden bio-ink. This study investigated the bioprinting of bio-inks with increasing 
concentrations of primary fibroblasts (1 x 106/mL, 10 x 106/mL, 20 x 106/mL and 40 x 
106/mL) without any bio-ink purges to investigate the number of cells dispensed into 
multiple wells of a 24-well plate over 60 minutes. The aim of this study was to establish 
a range of printable cell laden bio-inks. The total cell count and cell viability was 
observed with a haemocytometer as described in section 2.8 of chapter 2. Viability was 
assessed using a trypan blue exclusion assay. Cells from three separate donors were 
printed and counted. 
The cell count (number of cells counted) of fibroblasts printed over time is shown in 
Figure 5.2. The inks containing 1x106 cells/mL and 10x106 cells/mL reliably dispensed 
cells over 60 minutes although there was some variation in the number of cells counted 
at 15 minutes with both inks (Figure 5.2).  As the cell concentration within the ink 
increased to 20x106 cells/mL the initial cell count w\as greater than anticipated. The 
cell count at 0 minutes was 2.89x106 which dropped to 2.25x106 at 15 minutes. The 
cell counts further decreased ending with a mean of 1.88x106 by 60 minutes. When 
printing a cell concentration of 40x106 cells/mL the cell count consistently decreased 
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at each time point. At first 4.95x106 cells were printed at 0 minutes, this number 
decreased with each time point to 4.56x106, 3.96x106, 3.34 x106 2.57x106 cells printed 
at 15, 30, 45 and 60 minutes, respectively. The increase in standard deviation at a 
higher cell concentration (40x106 cells/mL) and the decrease in the number of ells 
printed over time suggested that some degree of cell sedimentation was occurring 
during printing. 
 
The cell counts for each cell concentration were compared to anticipated cell count this 
is shown in table 5.1. For bio-inks containing fibroblasts at concentrations of 1x106/mL, 
10x106/mL, and 20x106/mL mean cell counts close to expected cell numbers with 
reasonable variation. This data suggests that the cell laden bio-inks remained stable 
meaning that the cells remained in suspension and were dispersed adequately in the 
respective inks over 60 minutes. While the cell count of inks containing 40x106 
fibroblasts per mL was close to the expected number of cells the variation was poor. 
The increase in standard deviation (Table 5.1) suggested that the bio-ink was relatively 
unstable during printing. 


























Figure 5.2. Cell count of fibroblasts bioprinted at 15 minute intervals. The total 
number of cells printed and counted at time point 0, 15, 30, 45 and 60 minutes after 
loading into the printer reservoir. Error bars indicate standard deviation. N=3. 
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Table 5.1. Mean cell count and standard deviation of fibroblasts. Mean and 
standard deviation of bioprinted fibroblasts at various bio-ink concentration. N=3. 
 
The mean viability of cells in the bio-inks over time can be seen in Figure 5.3. 
Generally, the viability of the cells in the bio-inks decreased over time. At 0 minutes 
the lowest viability recorded was 92%. After 15 minutes the lowest cell viability was 
recorded to be 86%. As time progressed further loss of cell viability was observed 






Mean cell count 




1 0.1 0.155 0.0984 
10 1 1.03 0.269 
20 2 2.25 0.391 
40 4 3.87 0.905 





























Figure 5.3 Mean viability fibroblasts bioprinted at several time points. The 
viability of fibroblasts printed at time point 0, 15, 30, 45 and 60 minutes. Error bars 
indicate standard deviation. N=3. 
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Overall, the data from this study suggested that there was some degree of 
sedimentation of cells when printing bio-inks containing cells at 20 million cells/mL and 
40 million cells/mL. The bio-inks that containing fewer cells produced a stable output 
over 60 minutes, with the mean number of cells printed over 60 minutes close to the 
number of expected cells. However, the standard deviation increased as the cell 
concentration of the bio-inks increased (Table 5.1). The viability of the printed cells 
remained ideal within the first 30 minutes of printing. However, cells printed after 30 
minutes displayed a greater loss in viability as time progressed. 
5.2.3 Bioprinting of epidermal and dermal skin cells 
The next steps required to bioprint HSEs, was to print the correct number of primary 
dermal fibroblasts and primary keratinocytes to replicate the number of cells manually 
seeded when producing a 96-well format Skimune3D® HSE. Like the previous study 
the aim was to prepare, and print bio-inks containing fibroblasts or keratinocytes and 
compare the output to the number of cells required per 96-well scaffold. The 
methodology used to calculate the number of droplets required to print 20 µL per well 
(capacity of transwell inserts) is defined in section 2.7.4. Using equation 3 in section 
2.7.4 the size of the array needed to print 20 µL was found to be 15 droplets by 15 
droplets. This methodology was also applied to the work which followed this study. The 
cell counts for both the fibroblasts and keratinocytes printed into the wells of a 96-well 
plate can be seen in Figure 5.4. The mean cell count across wells and the standard 
deviation are shown in Table 5.2. The dermal bio-ink containing fibroblasts at a 
concentration of 25x106/mL reliably dispensed across wells (Figure 5.4). The mean 
fibroblasts cell count across all wells was 4.7x105±0.4 (Table 5.2). The bio-ink 
containing keratinocytes was also consistent across wells with a mean cell count of 
3.53x105±0.17. The mean viability of both cell types across three biological replicates 
is shown in Figure 5.5. The mean viability of the printed fibroblasts was 92±3%. The 








Table 5.2. Mean cell count and standard deviation of cells printed over a period 
of 60 minutes. Mean and standard deviation of bioprinted fibroblasts at various bio-
ink concentration. N=3. 











Fibroblasts 25 5 4.7 0.4 
Keratinocytes 20 3.5 3.53 0.17 
Figure 5.4. Cell counts of bioprinted skin cells. The mean cell counts of printed 




5.2.4 Bioprinting of human full-thickness skin equivalents 
To bioprint a 96-well based full-thickness skin equivalent the parameters, ink 
formulations and array size stablished in sections 5.2.1, 5.2.2 and 5.2.3 were used to 
sequentially print dermal and full-thickness skin equivalents. The culture media and 
incubation conditions use were defined in section 2.6.2. The resulting dermal and full-
thickness HSEs were formalin fixed, paraffin embedded, sectioned, and stained. 
Haematoxylin and eosin (H&E) staining was used to visualise the overall structure of 
the HSEs. 
Representative images of H&E stained bioprinted dermal and full-thickness HSEs are 
shown in Figure 5.6. The representative bioprinted dermal equivalent displayed in 
Figure 5.6a shows a good distribution of cells throughout the scaffold. A consistent 
layer of dermal fibroblasts could be seen lining the top surface of the scaffold. Within 
the scaffold clusters of cells could be seen near the upper surface of the Alvetex®. The 
number of cells within scaffold increased towards the bottom of the scaffold. 
Underneath the scaffold a thick layer fibroblast was visible. Fibres of eosin stained 
ECM produced by the fibroblasts were also observed with the scaffold. The 
representative H&E stained full-thickness HSE can be seen in Figure 5.6B. The dermis 
of the full-thickness HSE was well populated with thick layers of fibroblasts above and 
Figure 5.5 Mean viability of bioprinted fibroblasts and keratinocytes. The 




beneath the scaffold. A dense and even distribution of dermal fibroblasts could be seen 
within the scaffold. The epidermis of the HSE contained visible basal, spinous, granular 
and a very thin stratum corneum. The basal layer was located directly above the 
dermal-epidermal junction indicated by the dotted line, although this layer was 
inconsistent. The differentiating and superficially migrating keratinocytes formed a 
spinous layer. The layer of granular cells indicated by the darker and slightly speckled 





Figure 5.6. Representative images of haematoxylin and eosin stained 
bioprinted dermal and full-thickness HSEs. A) Representative image of a 
bioprinted dermal equivalent, black arrow indicates ECM. B) Representative image 
of a H&E stained full-thickness skin equivalent. Dotted line indicates dermal-
epidermal junction. Scale bar: 50 µm. 
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5.2.5 Structural validation of human skin equivalents 
In addition to H&E staining bioprinted full-thickness HSEs were also stained with Picro-
Sirius red to detect dermal collagen, periodic acidic-Schiff (PAS) to stain muco-
substances found in basement membranes and Verhoeff-van Gieson staining to 
distinguish any elastin fibres from collagen. The representative images of bioprinted 
96-well HSEs are presented in Figure 5.7. Picro-Sirius red staining of bioprinted full-
thickness skin equivalents showed that the dermis was heavily loaded with collagen 
as expected (Figure 5.7A). Large thick cross-linked collagen layers could be seen 
directly beneath the epidermis at the dermal epidermal junction. This layer of collagen 
could be seen across the dermis, supporting the formation of an epidermis. Collagen  
within the scaffold was stained with less intensity and visually appeared smaller within 
the dermis much like physiological human skin (Ueda et al. 2019). The cell nuclei and 
cytoplasm were stained dark orange rather than yellow due to over exposure to ethanol 
during stain differentiation and section dehydration. A sheet of cross-linked collagen 
was also visible at the bottom of the scaffold. Verhoeff–Van Gieson staining of 
bioprinted full-thickness HSEs (Figure 5.7B) did not reveal any elastin fibres or 
precursors which would have stained grey/black present in the dermis. The PAS 
detected glycoproteins (black arrows) however this was not representative of a uniform 





Figure 5.7. Representative images of bioprinted HSEs stained with Picro-Sirius 
red, periodic acidic-Schiff, and Verhoeff-van Geison staining. A) Picro-Sirius red 
staining, blue arrow indicates cross-linked collagen mesh at dermal-epidermal 
junction. B) Verhoeff-van Geison staining. C) Periodic acidic-Schiff staining. Black 




Immunofluorescence staining was used to stain different markers present throughout 
the different layers in the epidermis of bioprinted full-thickness HSEs (Figure 5.8). The 
negative control is shown in Figure 5.9. Cytokeratin 14 (CK14) was detected directly 
above the dermal-epidermal junction (white dotted line) indicating the presence of 
basal keratinocytes at the dermal epidermal junction. Basal keratinocytes begin 
superficially migrate, stratify and express cytokeratin 10 (CK10) when undergoing 
differentiation. CK10 was positively detected above basal keratinocytes indicating 
stratification and the formation of a spinous strata. Involucrin which is expressed in the 
same regions as CK10 was also detected above the basal strata. Loricrin which is 
present in the corneal envelope of the epidermis was also detected in the bioprinted 
HSEs. Overall, the bioprinted full-thickness HSEs featured the relevant epidermal 
differentiation markers within the correct regions of the epidermis showing that the 





Figure 5.8. Representative images of immunofluorescent stained bioprinted 
full-thickness HSEs. HSEs stained for CK14 (green), CK10 (red), involucrin (red) 





Figure 5.9. Null primary (negative control) images for immunofluorescent 
staining of bioprinted HSEs. Blue nuclear staining shown using Hoechst 33342. 





5.2.6 Functional in-vitro validation of human skin equivalents 
Once the relevant epidermal markers were detected and the development of a human 
full-thickness HSE confirmed, it was necessary to demonstrate the feasibility for in-
vitro applications of the bioprinted full-thickness Skimune3D® HSE. This required the 
bioprinting of fully autologous HSEs using the parameters identified earlier in this 
chapter. The bioprinted HSEs were co-cultured with autologous peripheral blood 
monocytes (PBMCs) which were isolated from donor whole blood as described in 
section 2.5. The methodology for establishing the co-culture was described in section 
2.9. The aim of this study was to establish an in-vitro platform which could be used to 
test therapeutic antibodies. As discussed in chapter 4, qualitative histological analysis 
of HSEs to identify proinflammatory immunotoxic reactions would not be feasible. For 
this reason, the levels of proinflammatory cytokines present within the supernatants of 
the co-cultures were quantified across three biological donors. Proinflammatory 
cytokines were quantified as expression of the cytokines would be elevated during an 
immune response, allowing the immunotoxicity of the monoclonal antibodies to be 
compared. The mean concentrations of the proinflammatory cytokines are presented 
in Figure 5.10. Analysis of supernatants for interferon gamma (IFN-γ) revealed 
elevated IFN-γ levels in co-cultures treated with Muromonab-CD3 (OKT3). Levels of 
IFN-γ secretion from OKT3 treated co-cultures were significantly increased (p<0.0001) 
when compared to controls and Tysabri. The detected levels of interleukin-10 (IL-10) 
were also elevated in OKT3 treated co-cultures. This level of secretion was significant 
(p<0.01) when compared to the media control. Secretion of interleukin-12 p70 (IL-
12p70) and interleukin-13 (IL-13) were consistent across all co-cultures and no 
statistical significance was observed. Interestingly analysis of interleukin-1 beta (IL-1β) 
secretion showed very little secretion from media control cultures while the other 
conditions showed high variability, no significance between conditions was observed. 
Secretion of interleukin-2 (IL-2) was shown to be increased in OKT3 co-cultures. This 
level of secretion was significant (p<0.01) when compared to the media and isotype 
controls. Interleukin-4 (IL-4) levels were found to be relatively steady across conditions 
with no statistical significance. Secretion of interleukin-6 (IL-6) was elevated in all co-
cultures with little variation between conditions. Tumour necrosis factor alpha (TNF-α) 
levels of OKT3 treated co-cultures were significantly increased (p<0.01) when 
compared to the media control. 
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The production of and application of each cytokine quantified from the supernatant of 
the autologous co-cultures is summarised in table 5.3. The elevated IL-2 levels in 
OKT3 (Muromonab) treated levels were significant when compared to the media and 
isotype controls, suggesting an OKT3 induced T cell response. This links to IFN-γ 
expression in OKT3 treated co-cultures, where T cells activated by IL-2 could then 
increase expression of IFN-γ. Interestingly, there was no statistical significance in 
secretion of both IL-4 and IL-13. IL-4 and IL-13 are both associated with a Th2 type 
response (Berger 2000; Swain et al. 1990), and the lack of expression of IL-4 and IL-
13 suggests that a Th2 immune response was not induced. The elevated expression 
of TNF-α is comparable to the use of OKT3 in-vivo while the levels of TFNα, IFN-γ and 
IL-2 are similar to cytokine profiles generated in in-vitro (Gaston et al. 1991; Römer et 
al. 2011). This study indicates that it is feasible to use fully humanised full-thickness 
bioprinted HSEs to identify the immunotoxicity of monoclonal antibodies in-vitro by 




Figure 5.10. Mean proinflammatory cytokine concentrations from autologous 
co-cultures. The concentrations of cytokines detected from the supernatants of 
autologous co-cultures. Detected concentrations of interferon gamma (IFN-γ), 
interleukin-10 (IL-10), interleukin-12 p 70 (IL-12p70A),  interleukin-13 (IL-13), 
interleukin-1 beta (IL-1β),  interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-
6) and tumour necrosis factor alpha (TNFα) are shown in (A),( B) (C), (D), (E), (F), 
(G), (H), and (I) respectively. Statistically significant differences between conditions 





The bioprinted dermal and full-thickness HSEs were similar in structure to handmade 
HSE produced in 96-well and 24-well formats (Figure 5.11). The fibroblast ECM layer 
lining the top of the bioprinted dermal HSEs was not only capable of withstanding the 
forces of dispensed droplets but also supported the formation of an epidermis without 
keratinocytes infiltration of the dermis. The arrangement of dermal collagen was 
identical to handmade dermal equivalents produced in the 96-well and 24-well format. 
The loose and unorganised arrangement of dermal collagen within the scaffold was 
similar in nature to the ECM structure of the papillary dermis of physiological human 
skin as presented in Chapter 3. When comparing the structure of the bioprinted tissue 
to previously handmade HSEs and physiological human skin (Figure 5.11) is shown 
that the bioprinted tissue is similar in structure to handmade HSEs and human skin. 
Verhoeff–Van Gieson staining of bioprinted HSEs did not reveal any elastin fibres or 
elastin precursors as expected. Interestingly, PAS did positively detect the presence 
of glycoproteins in the bioprinted HSEs, however this did not indicate the formation of 
a full and consistent basement membrane at the dermal-epidermal junction. The 
basement membrane consists of collagen type IV, collagen type VII, laminins, 









Figure 5.11. Comparison of the bioprinted HSE to other HSEs in this thesis and 
to human skin. A) Physiological human skin. B) Handmade 24-well HSE. C) 
Handmade 96-well HSE. D) Bioprinted 96-well HSE. Scale bars: 100µm. 
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Collagens type IV, type VII and perlecan are synthesised by both fibroblasts and 
keratinocytes and cannot be distinguished from the dermal collagen synthesised by 
fibroblasts within the HSEs (Morrissey and Sherwood 2015). Nidogens are primarily 
synthesised by the dermal fibroblasts (Breitkreutz et al. 2013) while keratinocytes are 
responsible for production of laminin-332 and laminin-551 are produced by the 
epidermal keratinocytes (Morrissey and Sherwood 2015; Sugawara et al. 2008). The 
regions of the dermal-epidermal junction in bioprinted HSEs with poor glycoprotein 
staining also featured an inconstant stratum basale. Additionally, missing components 
of the basement membrane at the dermal-epidermal junction has been linked to the 
apoptosis of basal keratinocytes (Sher et al. 2006), potentially explaining the formation 
of vacuoles in the epidermis of the HSEs. Alternatively, such vacuoles may simply be 
due to the primary keratinocytes undergoing senescence after prolonged culture. 
Senescent keratinocytes could in turn limit the production of a full basement membrane 
as healthy basal keratinocytes are necessary to from the structure of a basement 
membrane (Morrissey and Sherwood 2015; Sugawara et al. 2008). Differentiation and 
stratification of the epidermis was characterised by positive staining for cytoskeletal 
keratins, cornified envelope precursors and a marker of a cornified envelope by 
immunofluorescent staining. Staining for basal CK14 and supra-basal CK10 confirmed 
the formation of both the basal and spinous strata's confirming epidermal stratification. 
Staining for involucrin revealed the presence of a precursor marker for the cornified 
envelope while positive detection of loricrin suggested the formation of a cornified 
envelop. Overall, this data suggests that the bioprinted HSEs were representative of 
handmade HSEs and human skin.  
The modified Jetlab system retrofitted with solenoid micro dispensing valves 
demonstrated that droplet volumes could easily be manipulated by influencing the 
dwell time of the solenoid valve and the backpressure applied to the bio-ink reservoir. 
With the possibility to create a fold increase in droplet volume of greater than 7 (26.6 
µL at 100µs with 100mmHg to 209.8 µL at 1000µs and 500mmHg) this bioprinting 
platform exhibits some degree of flexibility. The output of the bioprinting system could 
be further increased as the maximum dwell time achievable with the Jetlab is 3276µs 
and maximum backpressure achievable 800mmHg. Increasing these parameters 
increases volume per droplet and decreases the number of droplets required per print, 
therefore reducing total deposition time which is preferable for a high throughput 
printing process. However, there may be some disadvantages to increasing the volume 
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per droplet. As the volume of each droplet increases the droplet also become larger in 
size resulting in elongation of droplet.  This can lead to the formation of ligaments and 
satellite droplets. The formation of satellite droplets can impact the impact the accuracy 
of deposited droplets and further reduce printing resolution (Jang, Kim, and Moon 
2009). The capability of the retrofitted Jetlab platform to dispense droplets in the range 
of nanolitres is comparable to other studies investigating the use of solenoid 
microvalves for bioprinting (Faulkner-Jones et al. 2013; Keriquel et al. 2017; Okubo et 
al. 2019). As expected microvalve based deposition produced a larger volume per drop 
than other typical drop-on-demand (DOD) processes such as inkjet and laser assisted 
bioprinting (LABP) which offer picolitre level resolution (Sekitani et al. 2008; Singh et 
al. 2010). This lower resolution per droplet is necessary for high through put deposition 
of cells at the concentrations required to create a bioprinted HSE.  
The inclusion of an agitation system to the bio-ink reservoirs allowed the Jetlab to 
reliably dispense cell laden bio-inks over a 60-minute period. The large number of cells 
printed initially with bio-inks containing 20x106 cells/mL and 40x106 cells/mL was 
largely attributed to the settling of cells within the reservoir into the valve inlet 
immediately after loading inks into the reservoir cartridge and before activation of the 
agitation system. The reproducibility of the number of cells dispensed at 20x106 
cells/mL was ideal but was not achieved with the bio-ink containing 40x106 cells/mL. 
However, this reproducibility may also be achieved when printing cells at higher 
concentrations. For applications which require a greater output reproducibility at larger 
cell concentrations could be improved by increasing the voltage applied to the agitator 
motor or by using a motor which can accommodate a higher rpm. This was not further 
investigated as bio-ink concentrations of 20x106 cells/mL and 25x106 cells/mL proved 
adequate for the biofabrication of HSEs. Overall, the modified Jetlab platform was 
shown to be capable of handling a variety of cell concentrations. The data presented 
in this chapter shows that this bioprinting platform could dispense cells at higher 
concentrations than DOD inkjet systems which typically use bio-inks containing <106 
cells/mL (Murphy and Atala 2014). However, it is yet to be investigated if the modified 
Jetlab printer could print cells at concentrations of up to 108 cells/mL as reported by 
LABP processes (Ackermann et al. 2010; Guillotin et al. 2010; Murphy and Atala 2014). 
The loss in fibroblast viability over time can be associated with maintaining adherent 
cells in suspension at suboptimal temperatures. Furthermore, testing of cell viability 
immediately post printing for both primary fibroblasts and keratinocytes yielded results 
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that were comparable to the microvalve based work of Lee et al, where fibroblast and 
keratinocyte viability where reported to be 95±2.3% and 85.5± 5.7% (Lee et al. 2009). 
This data suggested that cell loss immediately post printing using the solenoid fitted 
Jetlab platform was in line with data for microvalve based printing of skin cells 
established in literature. 
The rational for scaling down to a 96-well transwell platform was to increase the 
number of models that could be manufactured per donor and to potentially reduce 
development costs. In terms of development costs, the cost to isolate and bulk up cells 
for the previous 24-well format and the 96-well format was unchanged, was the lead 
for bulking of cells and HSE culture. However, cost per well of culture for skin 
equivalents from the 24-well format to 96-well format were reduced by a factor of 8 for 
submerged dermal and basal strata incubation, and a reduction by a factor of 10 for 
air-liquid interphase (ALI) incubation of HSEs. These reduction in costs were attributed 
to the reduction in the volume of media required from the 24-well format (1.6-1mL per 
HSE) to the 96-well (200µL-100 µL). As established in chapter 4 the overall number of 
cells required to produce a single HSE in the 96-well format was reduced from the 24-
well format. This reduction in cells per HSE improved the scalability of the HSE by 
allowing over a three-fold increase in the number of HSE to be produced per donor 
(Figure 5.12). This three-fold increase could be further expanded should the issues 
regarding keratinocyte culture and replicative capacity highlighted in this thesis be 
addressed in future work. As for reproducibility, the bioprinting platform proved to be 
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Figure 5.12. Comparing the maximum number of full-thickness HSEs 
manufactured from a single donor. 24-well information provided by Alcyomics. 
126 
 
• Restricts IL-4 
mediated IFN-
γ suppression 





8, and TNF-α 
Mckenzie and 
Matthews 2001 
IL-1β Monocytes and 
dendritic cells 




















CD4 T cells 
differentiation 
into Th2 cells 
(Chen et al. 2004) 




















cells, T cells and 
fibroblasts 
Table 5.3. Summary of pro-inflammatory cytokine panel. The production and 
function of the cytokines quantified from the supernatants of autologous co-cultures. 
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Chapter 6 General Discussion and Conclusions 
6.1 Achievement of Objectives 
This thesis aimed to develop handmade and bioprinted Skimune3D® human skin 
equivalents (HSEs) which would be comparable to human skin and to evaluate the use 
of the bioprinted HSEs to assess therapeutic antibodies in-vitro. As presented in this 
thesis the handmade Skimune3D® HSE established in the 6-well format by Hill et al 
(Hill et al. 2015) was successfully optimised manually to a 24-well format, manually 
scaled down further to a 96-well format and replicated using solenoid microvalve 
bioprinting (Figure 6.1). 
 
Figure 6.1. Histology of HSEs across all formats. A) Original 6-well HSE developed 
by Hill et al (adapted from Hill et al 2015), Scale bar: 100µm. B) Handmade 24-well 
HSE, scale bar: 100µm. C) Handmade 96-well HSE, scale bar: 100µm. D) Bioprinted 
HSE, scale bar: 100µm. 
The structure of the handmade HSEs in both the 24-well and 96-well formats and 
bioprinted HSEs were compared to human skin. The dermal extra-cellular matrix ECM 
within the HSEs was shown to be synthesised by primary human fibroblasts. This 
collagen matrix was reported to be essential for the creation of a separate dermis and 
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epidermis (Hill et al. 2015). The Picro-Sirius red staining of collagen in handmade and 
bioprinted HSEs revealed a saturated network of collagen, largely consisting of less 
stained collagen, similar in nature to the papillary dermis of physiological human skin. 
The staining of epidermal markers such as cytokeratin-14, cytokeratin-10, involucrin 
and loricrin were detected in the epidermis of both the handmade and bioprinted 
constructs. This suggested that the epidermis of both the handmade and bioprinted 
HSEs were representative of human skin. This was particularly true for the handmade 
24-well HSEs where the well organised epidermal strata were highly representative of 
physiological human skin. The scaling from a 24-well format to 96-well HSE allowed 
HSEs to be constructed with fewer cells whilst still being physiologically representative 
of physiological human skin. The number of dermal fibroblasts needed per scaffold 
was reduced from 2x106 in the 24-well format to 0.5x106 in the 96-well format, while 
the number of epidermal keratinocytes was reduced from 1x106 in the 24-well format 
to 0.4x106 in the 96-well format. This reduction in the number of cells per scaffold 
translated to an increase in the number of full-thickness equivalents that could be 
manufactured per donor. The bioprinted HSEs were used to determine the 
immunotoxicity of therapeutic antibodies in-vitro with the antibody Muromonab (OKT3) 
resulting in statistically significant expression of proinflammatory cytokines. By 
comparison, the therapeutic antibody Tysabri which is clinically used as an 
immunosuppressant did not elicit an immune response. This expression of 
proinflammatory cytokines revealed that it could be feasible to use bioprinted HSEs for 
in-vitro pre-clinical testing of therapeutic antibodies. 
6.2 Novelty 
There is an increasing interest in the development of bioprinted tissue for the in-vitro 
assessment of therapeutics although, to date, there is no bioprinted HSE which are 
commercially available or otherwise available in a 96-well format (Ma et al. 2018; 
Mazzocchi, Soker, and Skardal 2019). The successful bioprinting of Skimune3D® in a 
96-well format as reported in this thesis provides a foundation for future work to 
manufacture HSEs on an industrial scale. To the best of our knowledge this thesis 
describes the first example of in-vitro testing of therapeutic antibodies using a 96-well 
bioprinted, fully human, full-thickness HSE. To date there have been many attempts to 
bioprint human skin however there have been no published studies which demonstrate 
that printed skin could be used for in-vitro testing of therapeutic antibodies (Mazzocchi, 
Soker, and Skardal 2019). The novel application of a fully human bioprinted tissue 
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suitable for in-vitro testing of therapeutic antibodies may be highly beneficial to the drug 
development process of the pharmaceutical industry (Mazzocchi, Soker, and Skardal 
2019). This proof of concept demonstrated in this thesis could be potentially utilised 
during the different stages of the drug development pipeline for safety testing of drug 
candidates allowing early elimination or modification of problem candidates, as well as 
at the preclinical stage to prevent ‘late failure’ prior the clinical testing phase. 
6.3 Long Term Implications of the Research 
To date there have been many publications in the field of biofabrication exploring the 
use of drop-on-demand printing processes such as ink jetting, solenoid microvalves, 
and laser assisted bioprinting  (LABP) (Arai et al. 2011; Faulkner-Jones et al. 2013; 
Koch et al. 2012). Such studies focus on the biofabrication of constructs using the 
deposition of high viscosity bio-inks consisting of cell laden cross-linked gels or gel 
precursors (Lee et al. 2014; Michael et al. 2013). As a result, few studies investigate 
the use of cell laden low viscosity bio-inks, therefore, little information is reported on 
the barriers associated with the deposition of cell laden low viscosity bio-inks. The work 
outlined in this thesis investigated the impact of cell concentrations within low viscosity 
bio-inks and continuous agitation of cell-laden bio-inks within the printer reservoirs on 
the quantitative output of bioprinting cells suspensions over time in addition to the 
application of bio-ink purges before construction of HSEs. As reported, such factors 
required implementation and optimisation to utilise cell laden low viscosity bio-inks to 
successfully construct HSEs that are both physiologically representative and 
functional. By demonstrating the impact of such factors on printing output and 
reproducibility, this research may serve as a reference for future studies that aim to 
improve the printing performance of drop-on-demand (DOD) processes dispensing low 
viscosity bio-inks for tissue engineering applications. 
Currently all commercial HSEs are manufactured using traditional top-down tissue 
engineering techniques. Therefore such HSEs typically rely on non-human ECM, as is 
the case for many studies which have bioprinted HSEs (Hill et al. 2015; Koch et al. 
2012; Lee et al. 2014; Rasmussen et al. 2010). Therefore, commercially available 
HSEs are not compatible with assays that require fully autologous systems. This thesis 
has demonstrated a hybridised approach to tissue engineering, combining top-down 
and bottom-up methodologies to create a fully human HSE which are compatible with 
fully autologous assays. As reported, the biologically inert scaffold-based approach 
allows the formation of a fully human HSE. The bioprinting of viable and functional 
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human cells using solenoid microvalves circumvents the labour-intensive aspect of 
creating 96-well tissue constructs on a large scale. This unique approach enables the 
production of biologically representative and functional HSEs that may be developed 
on a scale suitable for industrial demand.  
The approach described in this thesis could be a possible alternative to currently 
established methods to bioprint HSE’s which successfully represent human tissue. 
This approach could potentially be applied to wider applications such as disease 
modelling and modelling of wound healing. However, it is acknowledged that these 
applications may be only achievable in the long-term as the technology is further 
developed and validated. 
In terms of development and use of human HSE’s, Skimune3D® offers the benefit of 
the availability of tests which offer non-animal testing and provide the added benefit of 
avoiding cross species reactivity which can impact data interpretation.    
6.4 Conclusions 
• The successful solenoid microvalve based bioprinting of Skimune3D® in a 96-well 
format as reported in this thesis provides a foundation for future work to 
manufacture HSEs on an industrial scale.  
• Primary human skin cells were shown to be viable post printing and were shown to 
retain the functional capabilities required of the cells to generate HSEs.  
• The co-culture of autologous bioprinted HSEs with autologous peripheral blood 
monocytes (PBMCs) successfully identified positively and negatively immunotoxic 
therapeutic antibodies.  
Overall, this thesis demonstrates that bioprinted human tissue can bridge the gap 
between preclinical testing of drugs and first in man studies by identifying adverse 
immune response in-vitro triggered by therapeutic antibodies. 
6.5 Recommendations for Future Work 
The main limitation for scalable manufacturing of the bioprinted skimune3D® presented 
in this research is the in-vitro replicative capacity of isolated primary human 
keratinocytes. In this thesis, it was reported that replicative senescence and terminal 
differentiation in the later passages of keratinocyte culture could adversely affect the 
formation of the epidermal layer (Lundberg et al. 2000; Rheinwald and Green 1975). 
Therefore, future research should investigate keratinocyte propagation and 
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maintenance of the healthy basal phenotype; this could be achieved through three 
possible methodologies. Firstly, keratinocytes could be cultured with the Rho kinase 
inhibitor Y-27632 to boost proliferative capacity of the epidermal keratinocytes while 
limiting premature differentiation (Anderson et al. 2018; Chapman et al. 2010; 
Chapman et al. 2014; Strudwick et al. 2015). Secondly, the use of autologous feeder 
cells could increase the yield of keratinocytes per passage. The extra-cellular 
secretions of autologous dermal fibroblast feeder cells could boost proliferation, 
allowing lower inoculation densities for keratinocytes (Llames et al. 2015). Thirdly, the 
use of hydrophobic tissue culture plastic may increase keratinocyte population 
doubling times and, therefore, should be investigated (Hasskarl et al. 2005). By 
investigating each of the mentioned methodologies it may be feasible to increase the 
overall number of keratinocytes available to be printed, therefore increasing the 
potential number of full thickness HSEs developed per donor. Consequently, future 
studies should also explore the scalability of the Skimune3D® HSE by investigating 
how many HSEs can be printed per donor by means of incorporating improvements to 
keratinocyte culture. It should be investigated whether Skimune® could be scaled up 
beyond its current capacity of testing 12-13 molecule/drugs per donor to match the 
capacity of current 2D high-throughput screening which is routinely used by drug 
developers (Stebbings et al. 2013).  
Furthermore, the proof of concept for immunotoxicity testing of therapeutics using 
bioprinted tissue demonstrated in this thesis should be further validated. Further 
validation will require a larger donor cohort (n=10) to account for any variations in 
immune response between individuals and would necessitate testing of a wider range 
of therapeutic antibodies. For a true comparison of the HSEs functional use in-vitro this 
data could be compared back to an equivalent assay using physiological human skin 
(Skimune®). This would provide a direct side by side comparison between the in-vitro 
functionality of the Skimune3D® HSE against physiological human skin. 
Future work should also explore methods of reducing the overall lead-time of HSE 
development. This could involve alteration of the basal incubation time for 
keratinocytes seeded onto HSEs and potential changes in culture time at air-liquid 
interface (ALI). To further reduce development lead-time while maintaining an 
autologous system, future work could investigate the sequential printing of a cell laden 
dermis and an epidermis by using rapid bioprinting of dermal compartment in-situ. This 
could be achieved by isolating human fibrin from donor matched whole blood 
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